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CHAPTER I
General introduction
Updated and Adapted from: 
L Bollen, YM van der Linden, RHMA Bartels, PDS Dijkstra. 
The treatment of patients with spinal metastases in the Netherlands. 
Ned Tijdschr Oncol 2012;9:81-8.
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INTRODUCTION
Due to a rise in the incidence of malignant disease, as well as increased overall 
survival rates of patients with cancer, the incidence of metastatic disease is on the 
rise.1-4 Following lung and liver, bone is the third most common site of metastatic 
spread5 and, depending on the extent and location, can be the cause of pain, 
pathologic fractures and neurologic deficit, resulting in a reduced quality of life.
Bone metastases are most commonly caused by breast, prostate and lung cancer. 
Other, less frequently observed primary malignancies are colorectal, kidney and 
upper-gastrointestinal cancers.6 Depending on the primary tumor causing the 
bone metastasis, the lesions can have a lytic, sclerotic or mixed appearance. The 
spinal column is the most frequently affected by bone metastases, followed by the 
long bones and pelvis.7,8
Several types of spinal metastases are recognized. Intramedullary metastases are 
located within the spinal cord itself, whereas leptomeningeal metastases are located 
within the subarachnoid space. These types of spinal metastases are quite rare and 
are usually seen in end-stage disease. Spinal epidural metastases are located on the 
outside of the dura mater and the vast majority originates from the osseous parts 
of the spinal column. 
In 90-95% of patients with spinal bone metastases (SBM), pain is the first presenting 
symptom.9,10 Patients can experience pain either due to fracturing or collapse of 
the vertebral body, pressure on the periosteum from within the vertebra, or nerve 
root compression. Neurologic deficit due to SBM mainly presents as sensory or 
motor deficit through nerve root compression, but in its most severe form, SBM 
can compromise the spinal cord or cauda equina, leading to paraplegia or cauda 
syndrome. This occurs approximately in 3% of patients with SBM11 and can be an 
indication for emergency treatment with either radiotherapy or surgery.
Magnetic Resonance Imaging (MRI) is the modality of choice for demonstrating 
SBM (figure 1). It is capable of showing osseous metastatic disease, as well as 
providing essential information on spinal cord and nerve root compression.12-14 
Both T1 and T2 weighted images are necessary, preferably in both axial and 
sagittal planes.15,16 SBM are generally hypo-intense on T1 weighted images and, 
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depending on their lytic of blastic characteristics, can be hyper- or hypo-intense 
on T2 weighted images, respectively. Gadolinium enhancement is not required 
for demonstrating SBM, however, leptomeningeal metastatic disease can be 
missed without the addition of contrast. Computed Tomography (CT) is required 
for surgical or radiotherapy planning, if an indication for treatment is present. 
Conventional X-ray has little added value in the diagnostic phase, but can be 
helpful in a post-operative setting. If the primary tumor is unknown at the time of 
diagnosis of the SBM, PET-CT imaging should be performed, complemented with 
a biopsy of one of the suspect lesions. Timing of all investigations should depend 
on the presence or absence of any neurologic symptoms requiring emergency 
treatment.
Figure 1. CT-scan versus T1-weighted MRI. Notice the hypo-intense lesion in the vertebral body of Th11 on 
MRI, which cannot be seen on the CT-scan
 
TREATMENT OF SPINAL BONE METASTASES 
Therapy for symptomatic SBM consists of a local treatment through radiotherapy 
or surgery, or a combination of both, combined with adequate pain medication 
and – in the case of neurological deficit caused by spinal cord or nerve root 
compression – corticosteroids. Generally speaking, treatment will be palliative in 
nature and aimed at alleviating the aforementioned symptoms and achieving local 
control of the metastasis, thereby improving, or at least stabilizing the quality of 
life of the patient.
Radiotherapy is considered the cornerstone of treatment, achieving a 60-80% 
decline in pain and improving neurologic symptoms in 10-90% of cases.17-20 The 
major benefit is that it is non-invasive and any side-effects are generally transient 
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in nature and well tolerated. The downside is that the effects take several days 
to weeks to become apparent, making it inferior to surgery in the acute setting 
of severe neurological deficits. Also, radiotherapy is not indicated in the case of 
spinal instability, as this would require surgical fixation for proper management. 
Surgical techniques range from minimal invasive options to en-bloc resection of 
the affected spinal segments. Vertebroplasty, kyphoplasty or percutaneous pedicle 
screw fixation can also be combined with radiofrequency ablation (RFA) in order to 
achieve better local control. Open techniques include decompressive surgery and 
corpectomies, which should always be followed by fixation of the spinal column 
in order to ensure stability. Even though these techniques are highly effective in 
achieving local control and alleviating or avoiding neurologic symptoms, the 
complication rate is high (20-33%)21 and recovery from major surgery can be 
especially challenging in this fragile patient population. Therefore careful patient 
selection with a focus on extent of disease, life expectancy and patient preference 
is needed in order to avoid overtreatment.
 
PROGNOSTIC MODELS
Prediction of survival has become an integral part of selecting the appropriate 
treatment for patients suffering from symptomatic spinal bone metastases (SBM). 
Depending on the symptoms, patients with a short expected survival are most likely 
to benefit from short radiotherapy regimens, best supportive care or minimally 
invasive surgery. Patients with a relatively long expected survival could in some 
cases benefit from high dose radiotherapy or – in the case of radioresistant tumors 
and biomechanical instability – more extensive surgical interventions. Several 
studies have shown that the estimation of survival by clinicians in terminally ill 
patients is inaccurate and have suggested the use of prognostication models in 
order to prevent exposure of patients to unnecessarily extensive treatments.22-24 
Models to aid in the decision making process have been developed by Tokuhashi, 
Tomita and Van der Linden, amongst others.25-27  These models encompass 
prognostic factors such as primary tumor type, amount and location of spinal 
metastases, presence of visceral, brain and extraspinal bone metastases, functional 
status and neurological status. However, clinical applicability seems limited due 
to over- or under treatment and especially when predicting short survival the 
existing models fall short.28,29 
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THESIS OUTLINE 
Given the problems of patient selection described above, the primary aim of this 
thesis was to provide clinicians an accurate and easy to use risk stratification 
tool for survival, in order to guide clinical decision making. Chapter II presents 
a systematic review of risk factors for estimating survival in patients with SBM. 
Available literature over a period of sixteen years was studied and a level of 
evidence synthesis was performed to provide an insight into which risk factors 
are essential for accurate patient selection. Chapter III investigates the effect of 
risk factors on survival for surgically treated patients and gives an overview of 
postoperative complications. Chapter IV is the focal point of this thesis and 
describes a large retrospective series of patients treated with radiotherapy and/
or surgery for symptomatic SBM. In this chapter the clinical model to assess 
survival is developed and validated on an external dataset. Chapter V provides an 
adjustment of the prognostic model presented in the previous chapter. It aims to 
further specify the most important risk factor primary tumor into more accurate 
subgroups. All available patients with SBM from breast cancer were stratified 
based on the molecular phenotype, resulting in a more accurate classification for 
this specific patient category. Chapter VI discusses the performance of the model 
presented in chapter IV and several other models available in the literature, based 
on an external dataset. Next to estimation of survival, assessing stability of the spine 
in metastatic disease is one of the major challenges in patient management. The 
Spinal Instability Neoplastic Score (SINS) provides a framework to guide clinicians 
and in Chapter VII the clinical applicability of the SINS is investigated. Finally, a 
general summary of this thesis is provided in Chapter VIII and conclusions, clinical 
implications and future perspectives are discussed in Chapter IX.
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ABSTRACT
Purpose. For the selection of treatment in patients with spinal bone metastases 
(SBM), survival estimation plays a crucial role in order to avoid over- and 
undertreatment. To aid clinicians in this difficult task, several prediction models 
have been developed, consisting of many different risk factors. The aim of this 
systematic review was to identify prognostic factors that are associated with 
survival in patients with SBM in order to support development of predictive 
models.
Methods. A systematic review was performed with focus on prognostic factors 
associated with survival in patients with SBM. Two reviewers independently 
selected studies for inclusion and assessed the risk of bias. A level of evidence 
synthesis was performed for each prognostic factor. Inter-observer agreement for 
the risk of bias assessment was determined by the kappa-statistic.
Results. After screening, 142 full-text articles were obtained, of which 22 met the 
eligibility criteria. A total of 43 different prognostic factors were investigated in the 
included studies, of which 17 were relevant to pre-treatment survival estimation. 
The prognostic factors most frequently associated with survival were the primary 
tumor and the performance status. The prognostic factors most frequently not 
associated with survival were age, gender, number and location of the SBM and 
the presence of a pathologic fracture.
Conclusion. Prognostication for patients with SBM should be based on an accurate 
primary tumor classification, combined with a performance score. The benefit of 
adding other prognostic factors is doubtful. 
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INTRODUCTION
Spinal bone metastases (SBM) are a frequently observed complication of malignant 
disease. Due to an increase in the survival times of patients with malignancies, the 
incidence of SBM is expected to rise over the years.1,2 The majority of symptomatic 
SBM are caused by breast, prostate and lung cancer (56-74%)3,4,5 and most 
commonly arise from the thoracic part of the spine (51-67%).4,6 Patients present 
with pain due to destruction of bone tissue and/or and neurologic complaints 
due to nerve root and/or spinal cord compression.7,8 Both radiotherapeutical and 
surgical interventions are effective in treating these symptoms. However, due to 
the relatively short life expectancy of these patients, overtreatment is a common 
problem. Therefore, an accurate estimation of survival plays a pivotal role in 
selecting the appropriate treatment. Survival estimation by clinicians has been 
shown to be too optimistic9 and to provide an aid for this difficult task, several 
prediction models have been developed.4,8,10,11 These models employ different sets 
of prognostic factors such as performance score, primary tumor and the presence 
of visceral metastases to stratify patients with SBM according to survival risk, 
enabling clinicians to select a more appropriate treatment. Several studies have 
been undertaken to assess the prognostic value of these models and the factors 
being used.12,13 The aim of this systematic review was to identify prognostic factors 
that are associated with survival in patients with spinal bone metastases in order 
to help guide development of predictive models.
 
METHODS
Search strategy
The review protocol for this study was prospectively registered online at PROSPERO 
under registration number CRD42014006706 (www.crd.york.ac.uk/prospero). 
The search strategy was formulated in collaboration with a medical librarian to 
focus on the key terms survival, prognostic factors and spinal bone metastases, 
or variations thereof. The electronic databases Medline, Embase, Web of Science, 
Cochrane and Cinahl were searched from January 1999 up to September 2014. 
The complete search strategy is available as an online supplement.
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Eligibility criteria
Both prospective and retrospective studies were eligible for inclusion if they met 
the following criteria: (1) Sample size of at least 100 patients with spinal bone 
metastases from solid tumors (i.e. no hematological malignancies); (2) The study 
did not focus on one single primary malignancy; (3) Prognostic factors for survival 
were assessed by means of a multivariate analysis; (4) Studies were published in 
the English, German or Dutch language. If studies were derived from identical 
databases, the most comprehensive study was selected; separately published 
subgroup analyses were disregarded. Eligibility of studies was assessed by two 
independent review authors (W.J. and L.B.). A consensus meeting was planned to 
resolve disagreements. If disagreements persisted, a third review author (P.D.S.D.) 
was consulted.
Risk of bias
The risk of bias was assessed according to the guidelines provided by Hayden 
et al.14 In short, six main sources of potential bias (study participation, study 
attrition, prognostic factor measurement, outcome measurement, confounding 
and analysis) were assessed using a 29-item checklist. The six sources of bias were 
scored as being ‘high; 3 points’, ‘moderate; 2 points’, or ‘low; 1 point’. Therefore, 
the total number of points for each study ranged from 6-18, with a cut-off set at a 
maximum of 50% (≤9 points) for distinguishing a low risk of bias study from a high 
risk of bias study. Two review authors (W.J. and L.B.) independently scored the risk 
of bias for each study. A consensus meeting was planned to resolve disagreements. 
If disagreements persisted, a third review author (P.D.S.D.) decided on the risk of 
bias.
Data extraction
The data extracted from eligible studies consisted of the design, source of funding, 
setting, sample size, duration, inclusion and exclusion criteria, all prognostic 
factors investigated, duration of follow-up and results. If similar prognostic factors 
were investigated by different means, they were combined for the level of evidence 
analysis. For instance, the prognostic factor Performance status was assessed by 
means of the Karnofsky score15 or the Eastern Cooperative Oncology Group 
score.16 Other combined prognostic factors were Neurologic deficit; consisting of 
the Frankel score17 and ambulatory status, as well as the variable Primary tumor; 
consisting of several different sub classifications. Prognostic factors such as Age 
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and Number or location of SBM were also combined irrespective of any differences 
in cut-off points used. Two review authors (O.H and L.B.) extracted the data on 
standardized forms. When consensus could not be reached a third review author 
(P.D.S.D.) was consulted.
Statistical analysis
Statistical pooling of the results was not possible; therefore a level of evidence 
synthesis was performed for each prognostic factor. The levels of evidence were 
defined as follows:18,19
	 •	 	Strong evidence: consistent findings (≥75%) in multiple high-quality 
cohorts.
	 •	 	Moderate evidence: consistent findings (≥75%) in multiple cohorts, of 
which only one cohort was of high quality.
	 •	 	Limited evidence: findings of one high-quality cohort, or consistent 
(≥75%) findings in one or more low-quality cohorts.
	 •	 Inconclusive: inconsistent findings (<75%) irrespective of study quality.
Inter-observer agreement for the risk of bias assessment was determined by the 
kappa-statistic20. All analyses were performed using SPSS 20.0, Armonk NY, IBM 
Corp.
 
RESULTS
Study selection
The initial search yielded 4676 results (Medline n=1996; Embase n=1389; Web 
of Science n=1092; Cochrance n=145; Cinahl n=54). A total of 1687 duplicates 
were removed, leaving 2989 studies. After screening, 142 full-text articles were 
obtained, of which 120 did not meet the eligibility criteria: 33 studies were based 
on duplicate cohorts, 49 studies focused on a single primary tumor, 23 studies had 
less than 100 participants, 13 studies did not perform a multivariate analysis and 
two studies were excluded based on language. In total, 22 studies were included 
(figure 1).3,4,5,6,8,21-37 During the selection process, the reviewers disagreed on seven 
inclusions. Consensus was reached for all studies.
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Figure 1. Patient inclusion fl owchart.
Study characteristics
Th e characteristics of the 22 included studies are presented in table 1. Seven 
studies were based on prospectively collected data and the remaining fi ft een 
inclusions were retrospective studies. Th e population of seven studies consisted 
of surgically treated patients only, whereas fi ve studies were based on patients 
treated with radiotherapy only. Nine studies consisted of a mixed population and 
the treatment details of one study were not reported. Duration of follow-up was 
reported in nine studies and ranged from 8 to 72 months. Median duration of the 
period of recruitment was 8 years and ranged from 1 to 20 years.
57647 Laurens Bollen.indd   22 05-08-19   09:44
SYSTEMATIC REVIEW
23
II
Ta
bl
e 1
. C
ha
ra
ct
er
ist
ic
s o
f t
he
 2
2 
in
clu
de
d 
stu
di
es
. S
U
R:
 p
at
ie
nt
s t
re
at
ed
 w
ith
 su
rg
er
y. 
RT
C:
 p
at
ie
nt
s t
re
at
ed
 w
ith
 ra
di
ot
he
ra
py
 o
r c
on
se
rv
at
iv
e t
he
ra
py
. N
R:
 n
ot
 re
po
rt
ed
St
ud
y I
D
Au
th
or
, y
ea
r, 
co
un
tr
y
St
ud
y t
yp
e
No
. p
at
ie
nt
s
%
 SU
R/
RT
C
Fo
llo
w-
up
Pe
rio
d 
re
cr
ui
tm
en
t
Du
ra
tio
n 
re
cr
ui
tm
en
t
Ri
sk
 of
 B
ia
s
1
H
elw
eg
, 2
00
0,
 D
en
m
ar
k
Pr
os
pe
ct
iv
e
15
3
0/
10
0
N
R
19
96
-1
99
9
4 
ye
ar
s
H
ig
h
2
Ri
eg
el,
 2
00
2,
 G
er
m
an
y
Re
tro
sp
ec
tiv
e
13
9
N
R
N
R
19
90
-1
99
7
8 
ye
ar
s
H
ig
h
3
Li
nd
en
, 2
00
4,
 N
et
he
rla
nd
s
Pr
os
pe
ct
iv
e
34
2
0/
10
0
16
 m
on
th
s
19
96
-1
99
8
3 
ye
ar
s
Lo
w
4
H
os
on
o,
 2
00
5,
 Ja
pa
n
Re
tro
sp
ec
tiv
e
17
6
10
0/
0
23
 m
on
th
s
19
85
-2
00
1
16
 y
ea
rs
H
ig
h
5
Ib
ra
hi
m
, 2
00
8,
 In
te
rn
at
io
na
l
Pr
os
pe
ct
iv
e
22
3
10
0/
0
N
R
20
02
-2
00
3
2 
ye
ar
s
H
ig
h
6
Ch
i, 
20
09
, U
SA
Pr
os
pe
ct
iv
e
10
1
50
/5
0
8 
m
on
th
s
19
92
-2
00
2
11
 y
ea
rs
H
ig
h
7
A
rr
ig
o,
 2
01
1,
 U
SA
Re
tro
sp
ec
tiv
e
20
0
10
0/
0
N
R
19
99
-2
00
9
11
 y
ea
rs
Lo
w
8
Ba
rt
els
, 2
01
1,
 In
te
rn
at
io
na
l
Re
tro
sp
ec
tiv
e
56
7
9/
91
N
R
19
96
-2
00
8
13
 y
ea
rs
Lo
w
9
M
iz
um
ot
o,
 2
01
1,
 Ja
pa
n
Re
tro
sp
ec
tiv
e
60
3
0/
10
0
19
 m
on
th
s
20
02
-2
00
7
5 
ye
ar
s
Lo
w
10
Pa
rk
, 2
01
1,
 K
or
ea
Re
tro
sp
ec
tiv
e
10
3
10
0/
0
26
 m
on
th
s
20
01
-2
00
8
8 
ye
ar
s
H
ig
h
11
Po
in
til
la
rt
, 2
01
1,
 F
ra
nc
e
Pr
os
pe
ct
iv
e
14
2
83
/1
7
N
R
20
05
-2
00
7
3 
ye
ar
s
Lo
w
12
W
ib
m
er
, 2
01
1,
 A
us
tr
ia
Re
tro
sp
ec
tiv
e
25
4
25
/7
5
36
 m
on
th
s
19
98
-2
00
6
9 
ye
ar
s
Lo
w
13
Ch
ao
, 2
01
2,
 U
SA
Re
tro
sp
ec
tiv
e
17
4
0/
10
0
9 
m
on
th
s
20
06
-2
00
9
4 
ye
ar
s
H
ig
h
14
Ka
ta
ok
a, 
20
12
, J
ap
an
Re
tro
sp
ec
tiv
e
14
3
50
/5
0
21
 m
on
th
s
19
90
-2
00
8
19
 y
ea
rs
Lo
w
15
Ta
nc
io
ni
, 2
01
2,
 It
al
y
Re
tro
sp
ec
tiv
e
15
1
10
0/
0
N
R
20
04
-2
00
7
4 
ye
ar
s
H
ig
h
16
Ya
ng
, 2
01
2,
 K
or
ea
Re
tro
sp
ec
tiv
e
21
7
10
0/
0
N
R
20
01
-2
00
9
9 
ye
ar
s
Lo
w
17
Ba
la
in
, 2
01
3,
 U
K
Pr
os
pe
ct
iv
e
19
9
52
/4
8
N
R
20
10
-N
R
N
R
H
ig
h
18
Ra
de
s, 
20
13
, G
er
m
an
y
Re
tro
sp
ec
tiv
e
20
29
0/
10
0
N
R
19
92
-2
01
1
20
 y
ea
rs
H
ig
h
19
Ta
bo
ur
et
, 2
01
3,
 F
ra
nc
e
Re
tro
sp
ec
tiv
e
14
8
10
0/
0
24
 m
on
th
s
20
04
-2
01
0
7 
ye
ar
s
Lo
w
20
Bo
lle
n,
 2
01
4,
 N
et
he
rla
nd
s
Re
tro
sp
ec
tiv
e
10
43
5/
95
72
 m
on
th
s
20
01
-2
01
0
10
 y
ea
rs
Lo
w
21
M
or
ge
n,
 2
01
4,
 D
en
m
ar
k
Pr
os
pe
ct
iv
e
54
4
16
/8
4
N
R
20
11
1 
ye
ar
H
ig
h
22
Ye
un
g,
 2
01
4,
 H
on
g 
Ko
ng
Re
tro
sp
ec
tiv
e
12
8
46
/5
4
N
R
20
01
-2
01
1
11
 y
ea
rs
H
ig
h
57647 Laurens Bollen.indd   23 05-08-19   09:44
CHAPTER II
24
Risk of bias
Of the 22 included studies, agreement on the overall risk of bias was obtained for 
18 (82%). Consensus was reached for the remaining four studies. Inter-observer 
agreement for the overall risk of bias was substantial (kappa 0.62). Lower levels of 
agreement were mainly observed in the categories study participation (kappa 0.19) 
and confounding (kappa -0.13). 
Prognostic factors levels of evidence
A total of 43 different prognostic factors were investigated in the 22 included 
studies. Seven prognostic factors pertained to post-treatment details and four 
prognostic factors were specific to the received treatment of the patients in the 
cohort. These prognostic factors were therefore not considered relevant to pre-
treatment estimation of survival and were excluded. Fifteen prognostic factors 
were analyzed only once. As the level of evidence for these factors by definition 
could not exceed limited they are not mentioned in the results, but are presented 
in an online supplement. The remaining seventeen prognostic factors are detailed 
in table 2. Prognostic factors influencing survival in a certain study are mentioned 
in the column ‘positive association’ and studied prognostic factors not influencing 
survival are mentioned in the column ‘no association’.
Strong evidence for a positive association with survival was found for the primary 
tumor, performance status and the American Society of Anesthesiologists (ASA) 
classification.38 Strong evidence for no association with survival was found for 
gender, age, number of spinal bone metastases, location of spinal bone metastases, 
and the presence of a pathologic fracture. The evidence was inconclusive for 
visceral metastases, neurologic deficit, the interval between diagnosis of the 
primary tumor and start of treatment for SBM, the presence of extraspinal bone 
metastases, total number of bone metastases, pain, sphincter function, weight loss 
and cardiovascular disease.
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Table 2. Level of evidence for investigated prognostic factors. Numbers refer to study identification from 
table 1. ASA: American Society of Anesthesiologists. SBM: spinal bone metastases. Studies with a low risk 
of bias are in bold.
Prognostic 
factor
Positive association No association Level of evidence
Primary tumor 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 
14, 15, 17, 18, 20, 21, 22
13, 16, 19 Strong – 86%
Performance 
status
2, 3, 8, 9, 11, 12, 13, 17, 18, 19, 
20, 21, 22
14 Strong – 93%
ASA 
classification
11,19 Strong – 100%
Age 6, 9, 13 2, 7, 10, 11, 12, 14, 15, 16, 17, 18, 
19, 22
Strong – 80%
Gender 2, 8, 18 7, 9, 10, 11, 12, 13, 14, 16, 17, 
19, 22
Strong – 79%
Number SBM 21 2, 11, 12, 14, 16, 17, 18, 19, 20, 22 Strong – 91%
Location SBM 8 2, 7, 10, 11, 16, 19, 20, 22 Strong – 89%
Pathologic 
fracture
7,11,12 Strong – 100%
Visceral 
metastases
3, 9, 12, 14, 15, 17, 18, 19, 20, 
21, 22
2, 7, 11, 13 Inconclusive – 73%
Neurologic 
deficit
1, 4, 5, 7, 18, 21 2, 12, 14, 16, 17, 19, 20, 22 Inconclusive – 57%
Interval 
diagnosis
1, 13, 14, 18 15, 16 Inconclusive – 67%
Extraspinal 
bone 
metastases
14, 17, 18 12, 19, 20, 21, 22 Inconclusive – 63%
Number bone 
metastases
9,15 3,21 Inconclusive – 50%
Pain 4,11 14 Inconclusive – 67%
Sphincter 
function
5 7,11 Inconclusive – 67%
Weight loss 11 19 Inconclusive – 50%
Cardiovascular 
disease
11 19 Inconclusive – 50%
DISCUSSION
In this systematic review it is shown that the primary tumor, performance status 
and the ASA classification are associated with survival in patients with spinal bone 
metastases. Age, gender, number of SBM, location of SBM and the presence of a 
pathologic fracture are most likely not associated with survival.
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Even though the eligibility criteria for this study were strict, several limitations 
were observed. Firstly, 68% of the included studies were conducted retrospectively 
and 55% of the studies consisted of populations that were treated either only with 
surgery or only with radiotherapy. This increased the risk of bias and therefore the 
quality of our results. Also, the way the studies evaluated the prognostic factors 
was heterogeneous and several different cut-off points were used. 
The primary tumor was investigated as a potential prognostic factor in all but one 
study. Even though several different classifications were used, it was found to be 
associated with survival in 86% of the included studies, leaving no doubt that an 
accurate primary tumor classification is required for prognostication in patients 
with spinal bone metastases. The same applies to the performance status, with 
a positive association rate of 93%. Irrespective of which specific score is used, it 
provides essential information for accurate prognostication. The ASA classification 
was investigated in two studies with a low risk of bias and both found a positive 
association with survival. Because it is rather similar to the performance status, it 
remains to be seen whether there is a significant benefit to including both factors 
in a prognostic model.
Age was found not to be associated with survival in 80% of the included studies. 
Considering the fact that a performance score generally provides a much better 
measure of a patient's health – and therefore prognosis – than age does, it is not 
unexpected that this variable is not significantly associated with survival in a 
multivariate analysis. Gender also was not associated with survival, with a rate 
of 79%. Breast and prostate cancer make up a large percentage of the populations 
in the included studies. Since they are gender specific, it is not unlikely that any 
potential effect of gender is corrected on multivariate analysis. Gender might 
play a role in SBM prognostication for certain primary cancers with a more even 
distribution, such as lung cancer. Number and location of the SBM, as well as 
the presence of pathologic fractures, had no effect on survival in the majority of 
the included studies. Even though these factors are important to consider when 
deciding on treatment – for instance determining extent of radiation field or levels 
of surgical fixation – they most likely do not need to be considered with respect 
to survival.
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The rate of positive association for the presence of visceral metastases was 73%, 
meaning the level of evidence was only just inconclusive. A recent study that 
stratified the risk factor analysis based on the primary tumor classification found 
that the effect of visceral metastases on survival changed between different tumor 
categories4. The survival of patients with a fast growing, aggressive tumor was 
not affected by visceral metastases, whereas patients with a slow growing tumor 
did have a significantly shorter survival when visceral metastases were present. 
The included low risk of bias studies that found a positive association had, on 
average, 10% more breast cancer patients in their population than studies that did 
not find an association. This difference in composition of the population might 
explain the different findings in these studies. The prognostic factor neurologic 
deficit consisted of two variables; ambulatory status and the Frankel classification. 
Because of the interaction with the performance status of a patient, this variable 
can be difficult to obtain, especially retrospectively. Even though it is an important 
variable to consider when deciding on type of treatment, it is unclear whether this 
variable plays a role in estimating survival. 
In conclusion, prognostication for patients with SBM should be based on an 
accurate primary tumor classification, combined with a performance score. The 
added benefit of including the ASA classification should be studied further, as 
should the influence of visceral metastases and the presence of neurologic deficit.
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ABSTRACT
Purpose. Evaluation of risk factors for survival in patients surgically treated for 
symptomatic spinal epidural metastases (SEM).
Methods. One-hundred-and-six patients who were surgically treated for 
symptomatic SEM in a ten-year period in two cooperatively working hospitals 
were retrospectively studied for nine risk factors: age, gender, site of the primary 
tumor, location of the symptomatic spinal metastasis, functional and neurologic 
status, the presence of visceral metastases and the presence of other spinal and 
extraspinal bone metastases. Analysis was performed using the Kaplan-Meier 
method, univariate log-rank tests and Cox-regression models.
Results. Overall median survival was 10.7 months (0.2 – 107.5 months). Overall 
30-day complication rate was 33%. Multivariate Cox-regression analysis showed 
that fast growing primary tumors (HR 3.1, 95%CI 1.6-6.2, p=0.001), the presence 
of visceral metastases (HR 1.7, 95%CI 1.0-2.9, p=0.033) and a low performance 
status (HR 2.7, 95%CI 1.1-6.6, p=0.025) negatively influenced survival.
Conclusion. Primary tumor type, presence of visceral metastases and performance 
status are significant predictors for survival after surgery for symptomatic SEM 
and should be evaluated before deciding on the extent of treatment. More accurate 
prediction models are needed to select the best treatment option for the individual 
patient.
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INTRODUCTION
Symptomatic spinal epidural metastases (SEM) continue to be a disabling 
consequence of cancer, causing a decrease in quality of life due to pain and 
neurological decline. With the development of better treatment options for the 
primary cancer, survival periods in metastatic disease will increase and will most 
likely lead to a rise in the incidence of metastatic spine disease. There is consensus 
on the fact that surgery can be beneficial to patients presenting with SEM,1-3 
however, the optimal type of surgery to be used on an individual patient remains 
unclear. The goals of surgical intervention are to relieve pain and neurologic deficit 
by decompression of the spinal cord or cauda equina and stabilization of the spine. 
Surgical strategies to achieve these goals vary greatly in extent of tumor removal 
(ranging from debulking to en bloc resection of the affected vertebra) and type of 
stabilization (ranging from none to circumferential reconstruction with vertebral 
body replacement). Secondary to open surgery, minimal invasive techniques such 
as percutaneous vertebroplasty (PVP) or kyphoplasty and percutaneous pedicle 
screw fixation are increasingly used.
In practice the surgeon will match the type of surgery to the expected survival 
time, thus balancing the increase in morbidity associated with more extensive 
surgery to the expected gain in quality of life and mobility.
Models to aid in the selection of surgical candidates have been developed by 
Tokuhashi4,5, Tomita6, Van der Linden7 and Bauer8. Disadvantages of these models 
are that they vary in the amount and type of risk factors used (table 1) and the 
weight assigned to each of these factors, resulting in different scores for the same 
patient. Also, patient populations on which the models are based differ greatly; 
Van der Linden used data of radiotherapy patients only and Bauer based his model 
on a mixed group of patients with bone metastases to the extremities as well as the 
spine. As a consequence, the use of such a model entails a risk of over- or under 
treatment and clinical applicability is limited.
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Table 1. Six risk factors used in the four predictive models.
Tomita Tokuhashi Vd Linden Bauer
Primary tumor X X X X
Karnofsky performance status X X
Visceral metastases X X X X
Extraspinal bone metastases X X X
Number spinal metastases X X X
Frankel classification X
 
Since life expectancy is of such great influence on therapeutic decision-making, its 
accurate prediction is of the utmost importance.
The goal of this study is to retrospectively identify clinically relevant risk factors 
for estimating survival in 106 patients who were surgically treated in a ten-year 
period at our two centers.
 
MATERIALS AND METHODS
Patients
All patients who were surgically treated for symptomatic SEM between January 
2001 and December 2010 by one surgical team in two tertiary referral centers in 
the Netherlands were included. Forty-seven patients were operated at the Leiden 
University Medical Center and 59 at the Medical Center Haaglanden. The surgical 
team performed the spinal interventions in both hospitals. Surgical treatment was 
defined as all invasive procedures, aimed at palliation or control of symptoms of 
SEM. These procedures consisted of percutaneous vertebroplasty, intralesional 
decompression, partial or complete corpectomy and a single en bloc resection, 
either through an anterior, posterior or combined approach. Choice of technique 
and approach were dependent on location of the metastasis, possibilities of fixation 
on adjacent levels, expected survival and surgeon preference.
Table 2 shows all baseline characteristics of the study population. One patient died 
during surgery due to myocardial infarction and was excluded from the analysis. 
For reasons of completeness, the patient is mentioned in the complication 
summary. A total of 106 patients were included in the study, 53 male and 53 
female. The mean age at surgery was 59.0 years. The most commonly affected part 
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of the spine was the thoracic region (56%). During the course of treatment for the 
symptomatic SEM, 9 patients underwent systemic treatment (i.e. chemotherapy 
and/or hormone therapy), 31 patients received radiation therapy, and 55 patients 
received both. Thirty patients had radiation therapy preoperatively and 56 
postoperatively. Forty-seven patients had no sign of neurologic deficit, indicating 
they were referred either for persisting pain, a pathologic fracture or for instability 
of the spinal column. The most prevalent primary tumors were breast (n=25), lung 
(n=20), kidney (n=19) and prostate (n=11) (table 3).
Table 2. Patient characteristics. SD: standard deviation. 
Characteristic Number (%)
Gender
    Male
    Female
53 (50)
53 (50)
Age (mean, years, SD) 59.0 ± 10.9
Center
    LUMC
    MCH
47 (44)
59 (56)
Location symptomatic spinal metastasis
    Cervical
    Thoracic
    Lumbar
23 (22)
60 (56)
23 (22)
Adjuvant therapy SEM, perioperatively
    None
    Systemic Therapy
    Radiation Therapy
    Both
Neurologic deficit
    No (Frankel grade E)
    Yes (Frankel grade A, B, C, D)
11 (10)
9 (9)
31 (29)
55 (52)
47 (44)
59 (56)
Table 3. Primary tumors and median survival for each primary. *Median could not be calculated, mean 
is given.
Primary tumor Number (%) Median survival (95% CI)
Breast
Lung
Kidney
Prostate
Colon
Sarcomas
Melanoma
Thyroid
Rectum
Esophagus
Pharynx
Other
25 (23)
20 (18)
19 (18)
11 (10)
6 (6)
5 (5)
4 (4)
3 (3)
2 (2)
2 (2)
2 (2)
7 (7)
34.7 (11.8 – 46.8)
6.9 (0.0 – 21.6)
14.9 (7.2 – 22.8)
9.2 (1.2 – 16.8)
1.7 (0.0 – 13.2)
8.8 (4.8 – 13.2)
3.4 (0.0 – 7.2)
35.6* (-)
2.1 (-)
3.9 (-)
7.2 (-)
2.7 (1.2 – 3.6)
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Seven patients underwent percutaneous vertebroplasty, 46 had limited posterior 
decompressieve surgery and 52 patients had extended decompressieve surgery in 
the form of an intralesional corpectomy. One patient was treated with an en bloc 
resection. (table 4).
Table 4. Surgical details. *Patients treated with percutaneous vertebroplasty excluded
Surgical details Number (%)
Type of surgery
    Percutaneous vertebroplasty
    Decompression w/o fixation
    Decompression with fixation
    Partial corpectomy
    Complete corpectomy
    En bloc resection
7 (7)
24 (22)
22 (21)
12 (11)
40 (38)
1 (1)
Approach
    Posterior
    Anterior
    Combined
86 (81)
11 (10)
9 (9)
Means of stabilization*
    No additional stabilization
    Pedicle screws / rods
    Cage with additional fixation
24 (24)
30 (30)
45 (46)
 
Risk factors
All available patient records were retrospectively studied for gender, age, site of 
the primary tumor, location of the symptomatic spinal metastasis, preoperative 
functioning according to the Karnofsky performance status (KPS)9,10, the presence 
of visceral metastases, the presence of other spinal and extraspinal bone metastases 
and neurologic functioning according to the Frankel classification11. Based on the 
survival data from this study, the primary tumor scores of the Tomita and Van der 
Linden models were adapted to better reflect the study population: in the Van der 
Linden model, kidney cancer was added to the ‘prostate group’ and thyroid cancer 
was added to the ‘breast group’. In the Tomita model, prostate cancer was moved 
to the ‘moderate growth’ category. KPS was scored in the period leading to surgery 
and not shortly before, to avoid the influence of acute neurologic decline. Date 
of surgery, date of complications and date of death were obtained from medical 
records or from general practitioners.
Statistical analysis
Survival time was calculated as the difference in months between date of surgery 
and date of death or last follow-up, with a minimum follow-up of eleven months. 
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Survival curves were estimated by using the Kaplan-Meier method. Influence of 
the risk factors was assessed by employing log rank tests for univariate analysis and 
for multivariate Cox analysis a backward stepwise procedure was used. A p-value 
of <0.05 was considered statistically significant. All analyses were performed using 
SPPS 18.0, SPSS Inc., Chicago IL.
 
RESULTS
Survival
The overall median survival was 10.7 months (0.2-107.5 months) (figure 1). Eighty 
patients (75%) died during follow-up, with a median survival of 6.5 months (0.2-
106.8 months). Twenty-five patients (24%) died within 3 months after surgery and 
13 patients (12%) died 3 to 6 months after surgery.
Figure 1. Overall survival.
 
The highest median survival time was found in patients with breast cancer (34.7 
months), followed by kidney (14.9 months) and prostate cancer (9.3 months). 
Patients with colon cancer had the lowest median survival (1.7 months). 
57647 Laurens Bollen.indd   37 05-08-19   09:44
CHAPTER III
38
Complications
Within 30 days after surgery, 35 patients (33%) had one or more complication with 
a total of 53 recorded complications.  Nine patients had multiple complications. 
The most common were wound infection (n=8), new minor neurologic deficits 
such as radicular pain or reduced sensibility (n=8), cerebrospinal fluid leak (n=6), 
and pneumonia (n=4) (see table 5). Three patients had to be re-operated due to 
instrumentation failure or acute neurologic decline. Ten patients died within 30 
days, mostly due to systemic complications such as sepsis and respiratory failure. 
The complication rate in this group was 70%.
Table 5. 30-day complications.  *Death occurred during surgery.
Complication Number (%)
Cardiac
    Myocardial infarction*
    Arrhythmia
    Extensive blood loss
1 (2)
2 (4)
1 (2)
Gastrointestinal
    Ileus
    Bleed
1 (2)
1 (2)
Infection
    Pneumonia
    Sepsis
4 (8)
2 (4)
Neurologic
    New minor deficits
    New major deficits
    Delirium
8 (15)
2 (4)
3 (6) 
Pulmonary
    Respiratory failure
    Pleural empyema
2 (4)
1 (2)
Renal
    Acute renal failure 1 (2)
Metabolic
    Hyponatremia
    Metabolic acidosis
1 (2)
1 (2)
Skeletal
    Pathologic fracture 1 (2)
Surgical site 
    Wound infection
    Wound dehiscence
    Wound leakage
    Hematoma
    Cerebrospinal fluid leak
    Instrumentation failure
8 (15)
1 (2)
1 (2)
2 (4)
6 (11)
3 (6)
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Univariate analysis of risk factors
Results for the univariate analysis are shown in table 6 and figures 2-4. All primary 
tumor classifications were significant predictors for survival after surgery. However, 
none of the classifications were able to systematically differentiate between all of 
their subgroups (see Appendix A). The absence of visceral metastases (p=0.014) 
had a significant effect on survival. Gender, location of the symptomatic spinal 
metastasis, number of spinal metastases, presence of other bone metastases, age, 
KPS and Frankel classification had no effect on survival after surgery.
Table 6. Results of univariate analysis. *Including spinal metastases
Univariate analysis p-value
Primary tumor classification
    Tomita (modified)
    Tokuhashi (revised)
    Van der Linden (modified)
    Bauer (modified)
<0.001
0.001
0.002
0.008
Karnofsky performance status
    100-80/70-50/40-10 0.169
Visceral metastases
    Present/removable/unremovable
    Present/not present
0.027
0.014
Bone metastases
    Solitary/multiple*
    0/1-2/≥3
0.946
0.970
Number of spinal metastases
    1/2/≥3 0.860
Frankel classification
    A+B/C+D/E 0.196
Age
    <65/≥65 0.089
Location
    C-Th6/Th7-L 0.163
Gender
    Male/female 0.159
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Figure 2. Primary tumor classification Tomita modified.
Figure 3. Visceral metastases.
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Figure 4. Karnofsky performance status.
 
Multivariate analysis of risk factors
A multivariate Cox regression analysis was performed by employing as risk 
factors primary tumor (Tomita modified, moderate growth HR 1.7, 95%CI 0.9-
3.3, p=0.099, fast growth HR 3.1, 95%CI 1.6-6.2, p=0.001), presence of visceral 
metastases (HR 1.7, 95%CI 1.0-2.9, p=0.033) and performance status (KPS 50-
70 HR 1.3, 95% CI 0.8-2.1, p=0.292, KPS 10-40 HR 2.7, 95%CI 1.1-6.6, p=0.025) 
(table 7). 
Table 7. Results of multivariate Cox-regression analysis. HR: Hazard ratio; 95% CI: 95% confidence interval
Multivariate analysis HR p-value 95% CI
Tomita tumor classification
    Slow  
    Moderate
    Fast
1.7
3.1
0.004
0.099
0.001
0.9-3.3
1.6-6.2
Visceral metastasis
    Present/not present 1.7 0.033 1.0-2.9
Karnofsky performance status
    80-100
    50-70
    40-10
1.3
2.7
0.077
0.292
0.025
0.8-2.1
1.1-6.6
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DISCUSSION
In this study on 106 patients operated for symptomatic SEM, primary tumor type, 
presence of visceral metastases and functional status were found to be significant 
predictors of survival. Other risk factors as gender, presence of other bone 
metastases, number and location of spinal metastases, age and neurologic status 
did not have an effect on survival.
For the purpose of accurately evaluating the individual risk factors, modifications 
to two items were made. We agree with Wibmer et al. that the primary tumor 
classifications are not up to date12. However, based on survival data in this study, 
the conclusion that patients suffering from kidney cancer have a prognosis 
comparable to those with breast cancer cannot be followed. Median survival in 
patients with prostate cancer was compatible with the ‘moderate growth’ category 
in the Tomita model and therefore it was decided to remove it from the ‘slow 
growth’ category. In 2004, Van der Linden et al. studied 342 patients with spinal 
metastases who were conservatively treated for pain by means of external beam 
radiation therapy7. Since patients with renal cell carcinoma were excluded and 
patients with thyroid cancer were underrepresented, these primary tumors are not 
mentioned separately in the model. Scoring these tumors in the ‘other’ category 
is incorrect and adjustments are needed: kidney cancer was added to the ‘prostate 
group’ and thyroid cancer was added to the ‘breast group’. 
The preoperative assessment of the Karnofsky performance score was standardized. 
In a patient population notoriously at risk for acute neurologic decline, we believe 
it is wrong to take such a measurement just prior to surgery because of the acute 
distorting effect of neurologic impairment on functional impairment. Therefore, 
it was decided by the authors that functional status had to be evaluated before the 
onset of acute neurologic decline.
When assessing primary tumor type, the Tomita classification was found to be 
the most practical and – after modification – also the most accurate of the four 
classifications. The difference in survival between slow and moderate growth 
tumors is not significant on both univariate (p=0.073) and multivariate analysis 
(HR 1.7, 95%CI 0.9-3.3, p=0.099), but the difference between slow and fast growth 
(p<0.001) and moderate and fast growth (p=0.007) is strongly significant.
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Even though the results of the Van der Linden classification improved after 
modification, accuracy is still lacking, as is the case for the Tokuhashi and Bauer 
classifications. An explanation for this finding may be the relatively long survival 
of patients with lung cancer in this study (median survival 6.9 months). Bias 
might have been introduced by selection of only those lung cancer patients with 
preoperative estimated long survival. Whereas in the Tomita classification this 
primary is mixed with other fast growing tumors such as melanoma (median 
survival 3.4 months) and colon cancer (median survival 1.7 months), the other 
classifications use this primary as a separate entity. This underlines another 
advantage of the Tomita tumor classification: its adaptability. We believe it 
is impossible to present a globally valid tumor classification, considering the 
differences in incidences and ever-changing treatment options. By creating 
categories based on contemporary regional survival data, results will be more 
accurate than when adhering to semi-rigid classifications as presented in other 
classifications.
As a marker for progression of disease, the presence of visceral metastases does 
not directly influence survival. In their models, Tomita and Tokuhashi make use 
of a third category, namely operability. Tokuhashi initially based this category on 
a single patient out of the 64 studied4 and Tomita on 7 out of 67 patients6. As is 
shown in the results, operable visceral metastases have a similar median survival 
when compared to no visceral metastases. Unfortunately, the treatable visceral 
metastases group only consisted of 6 patients. These results are most likely due to 
patient selection. If a patient is considered fit enough to undergo metastasectomy, 
survival will most likely be prolonged based on their general condition and not 
the removal of the visceral metastasis. A recent retrospective study of 504 breast 
cancer patients irradiated for metastatic spinal cord compression by Rades et 
al.13 also found a strong negative effect on survival if visceral metastases were 
present, similar to Wibmer et al., Yamashita et al. and Crnalic et al.12,14,15
Performance status is generally accepted as a strong prognostic factor for survival 
in metastatic disease16, but in case of spinal metastases it remains controversial. 
Even though both the Tokuhashi and the Van der Linden models make use of the 
KPS, evidence is still limited. In his article, Tokuhashi writes: “(…) the standard 
deviation was too great for the values to be sufficiently meaningful.4” 
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Pointillart et al.17 found the KPS to be a significant predictor of survival on 
univariate analysis, but unfortunately did not perform an analysis for each 
category. In their study the HR was equal to 0.98 (p=0.002, 95%CI 0.96-0.99), 
indicating that performance status was not clinically relevant.
In a retrospective study, evaluation of performance status is challenging, especially 
when trying to avoid the influence of neurologic deficit. The data does suggest an 
effect of performance status on survival, but only on multivariate analysis and when 
divided in three groups. The HR for a KPS score 50-70 is equal to 1.3, (p=0.292, 
95%CI 0.8-2.1), but the HR for a KPS score 10-40 is equal to 2.7 (p=0.025, 95%CI 
1.1-6.6). 
Chi et al.18 considered the effects of age in predicting survival as well as preservation 
of ambulation for patients treated for spinal metastases. We agree that particular 
age cutoff points can help in selecting patients, but did not find their suggested age 
of 65 to be accurate in this population (p=0.089).
Neurologic deficit has no significant effect on survival (p=0.196), stressing that 
this variable should be excluded when evaluating performance status. Even though 
survival is not affected by neurologic functioning, it is an important factor that 
should be considered when deciding on treatment. 
In patients with malignancies, the presence of bone metastases can be used as 
a marker for progression of disease. However, if a patient is already affected by 
spinal bone metastases, the presence or absence of extraspinal bone metastases is 
inconsequential. Neither the classification according to Tokuhashi (p=0.970), nor 
the classification according to Tomita or Bauer (p=0.946) resulted in a significant 
effect. The amount (p=0.860) and location (p=0.493) of spinal metastases have 
no impact on survival. Similar to neurologic functioning it does however have 
consequences when deciding on treatment. Feasibility, approach and extent of 
surgery should be weighed against amount of metastatic involvement of the spinal 
column and location of the symptomatic metastases.
Based on these results it can be argued that there are several flaws in the current 
scoring systems. Firstly, the primary tumor classifications need to be updated based 
on larger populations. Our experience is that the Tomita classification is the ideal 
57647 Laurens Bollen.indd   44 05-08-19   09:44
SURGICAL COHORT
45
III
framework for doing so. Secondly, several risk factors should be removed from 
the models. Other bone metastases, number of spinal metastases and neurologic 
deficit are all important factors to consider when deciding on surgery, but do not 
play a role in estimating survival. Lastly, provided neurologic deficit is excluded 
as a confounder, functional status should be included in any scoring system, as 
should the presence of visceral metastases. Currently, the only model to contain 
these risk factors, without the drawback of having to evaluate several others, is 
the Van der Linden model. If the primary tumor classification would be revised, 
preferably along the lines of the classification proposed by Tomita, this model 
would be superior in ease of use as well as accuracy.
Even though estimating survival is an important part of the decision-making 
process concerning the treatment of symptomatic SEM, it should never be the 
only point of interest. Neurologic symptoms and their duration, pain, feasibility 
of other treatment options, stability of the spinal column and expected gain in 
quality of life should all be discussed, preferably in a multidisciplinary setting.19
Complication rate in this study is high (33%). This is mainly due to the fact that 
only surgically treated patients were included and that surgical techniques used 
were aggressive (50% partial or complete corpectomy). A limitation of this study 
is its retrospective design and the fact that only surgically treated patients are 
evaluated. Therefore, patients who were referred for surgical consultation but did 
not receive treatment are not represented in this study. The wide array of surgical 
interventions used is due to the lack of clinical guidelines during the period 
described in this study. Also, the heterogeneity of primary tumors can cause 
discrepancies in recorded survival times of the smaller groups when compared 
with other studies.
Primary tumor type, presence of visceral metastases and functional status are 
strong risk factors for determining survival in patients operated for symptomatic 
spinal epidural metastases and should always be carefully evaluated.
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ABSTRACT
Background. Expected survival is a major factor influencing extent of treatment 
for symptomatic spinal bone metastases (SBM). Predictive models have been 
developed but their use can lead to over- or under treatment.. The study objective 
was to identify prognostic factors associated with survival in patients with 
symptomatic SBM and to create a validated risk stratification model.
Methods. All patients who were treated for symptomatic SBM between 2001 and 
2010 were included in this single center retrospective study. Medical records were 
reviewed for type of primary cancer, performance status, presence of visceral, brain 
and bone metastases, number and location of spinal metastases and neurological 
functioning. Performance status was assessed with the Karnofsky performance 
score (KPS) and neurological functioning with the Frankel scale. Analysis was 
performed using Kaplan-Meier curves, univariate log-rank tests, Cox-regression 
models and Harrell’s c-statistic.
Results. A total of 1043 patients were studied. The most prevalent tumors were 
those of breast (n=299), lung (n=250) and prostate (n=215). Median follow-up 
duration was 6.6 years and six patients were lost to follow-up. Based on the results 
of the uni- and multivariate analyses, four categories were created. 
Median survival in category A was 31.2 months (95%CI 25.2-37.3),  15.4 months 
(95%CI 11.9-18.2) for B, 4.8 months (95%CI 4.1-5.4) for C and 1.6 months (95%CI 
1.4-1.9) for category D. Harrell’s c-statistic was calculated after the model was 
applied to an external dataset, yielding a result of 0.69.
Conclusion. Assessing patients according to the presented model results in four 
categories with significantly different survival times.
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INTRODUCTION
Metastases to the spinal column are a frequently observed complication of end 
stage malignant disease. Dependent on their extent and localization, they cause a 
variety of clinical symptoms ranging from pain to neurological deficits and even 
paraplegia. These spinal bone metastases (SBM) most commonly arise from the 
posterior part of the vertebral body. When they extend into the epidural space and 
compress the spinal cord, the clinical entity is called malignant epidural spinal 
cord compression (MESCC)1. 
Due to improvements in systemic treatment options for the primary tumor, 
overall survival times in patients suffering from metastatic disease are on the rise. 
Most likely, this will result in a prolonged palliative phase in which the incidence 
of patients presenting with symptomatic SBM will increase. It has been well 
established that treatment with radiotherapy and/or surgery can be beneficial to 
patients presenting with pain, neurological deficit or both2-6. However, the most 
optimal treatment algorithm for individual patients is not optimized yet. In 
practice, the treating physician will match extent and type of treatment not only 
to a patient’s clinical presentation, but also to the expected survival time, thus 
balancing the increase in morbidity and mortality associated with more extensive 
treatment to the expected gain in quality of life.
Models to aid in therapy selection based on expected survival time have been 
developed by Tomita7, Tokuhashi8,9, Bauer10,11 and our own group4. These models 
encompass prognostic factors such as primary tumor type, amount and location 
of spinal metastases, presence of visceral, brain and extraspinal bone metastases, 
functional status and neurological status. However, clinical applicability seems 
limited due to over- or under treatment and especially when predicting short 
survival the existing models fall short12,13.
The goal of this study was to identify risk factors associated with survival and to 
develop a validated survival risk stratification model for patients with symptomatic 
SBM.
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MATERIALS AND METHODS
In this single center retrospective cohort study, all patients treated for metastases in 
the spinal column between January 2001 and December 2010 at a tertiary referral 
hospital in the Netherlands were included. Patients were identified through 
database searches linking treatment and diagnostic codes and through database 
searches based on surgical coding. Information on date of death was obtained 
from medical records or by contacting the general practitioner. 
Local treatment consisted of external beam radiotherapy for pain or minor 
neurologic deficit, surgery for rapidly progressive or severe neurologic deficit 
and instability, or a combination of both treatment modalities. Concomitant 
systemic anticancer treatments such as chemotherapy and bisphosphonates were 
considered to be secondary to the local treatment. For external validation of the 
final model, the database of the Dutch Bone Metastasis Study (DBMS) was used14.
Due to the retrospective nature of the study, it is exempt from medical ethics 
review according to the Dutch Central Committee on Research Involving Human 
Subjects.
The primary data sources were the patient’s clinical files, radiology reports and 
admission forms. Baseline variables obtained before start of treatment were gender, 
age, primary tumor, location and number of SBM, the presence of visceral and/
or brain metastases, the presence of extraspinal bone metastases, pretreatment 
functioning according to the Karnofsky performance status (KPS)15,16 and 
neurological functioning according to the Frankel classification17. 
The primary tumors were categorized based on the Tomita classification7. The 
original classification used growth speed alone to assign a primary tumor into 
one of three groups. However, as growth speed is not the only factor determining 
survival, we renamed the classification ‘clinical profile’ encompassing other 
contributing factors such as the availability of effective systemic treatment options 
for the primary tumor. The clinical profile of a primary tumor was considered to 
be favorable, moderate or unfavorable. 
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Performance status was dichotomized into normal functioning (KPS 100-80%) 
and impaired functioning (KPS 70-10%). Neurological functioning was inferred 
from clinical exams and divided into three groups: no deficit present (Frankel 
E), minor motor or sensory deficit (Frankel D) and major motor or sensory 
deficit (Frankel A, B, C). The number of spinal and extraspinal bone metastases 
was obtained from radiology reports and further subdivided in three categories 
according to Tokuhashi9. 
Statistical analysis
Survival time was calculated as the difference between start of treatment for the 
spinal metastasis and date of death or the last follow-up moment recorded. Survival 
curves were estimated using the Kaplan-Meier method. Follow-up was assessed by 
employing the reverse Kaplan-Meier method18. Cox proportional hazard models 
were fitted using Collett’s method, consisting of a univariate analysis, followed by 
multivariate backward and multivariate forward selection19. Harrell’s c-statistic was 
used for external validation of the predictive accuracy of the presented model20. 
It estimates the probability of concordance between predicted and observed 
responses. Survival curves were compared using log-rank tests. A p-value of <0.05 
was considered statistically significant. All analyses were performed using SPSS 
20.0, SPSS Inc., Chicago IL.
 
RESULTS
A total of 1301 patients were treated for symptomatic spinal metastases during the 
study period. After excluding patients with direct ingrowth of a primary tumor 
into the vertebra (n=23), patients with bone metastases in the sacral or sacroiliac 
region (n=105), leptomeningeal metastases (n=24), intradural metastases (n=14), 
metastases deriving from primary tumors of hematological or of unknown origin 
(n=44) and metastases deriving from rare primary tumors (n=42), 1049 patients 
remained eligible for analysis. Primary tumors classified as adenocarcinoma of 
unknown primary (ACUP) were not excluded. Six patients moved abroad shortly 
after finishing treatment and were lost to follow-up (figure 1).
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Figure 1. Patient flow diagram.
 
Table 1 summarizes the characteristics of the 1043 patients studied, of whom 542 
(52%) were male and 501 (48%) were female. The mean age at start of treatment 
was 64.8 years (SD ± 12.5 years). At presentation, the majority of patients had no 
(n=518; 50%) or only minor (n=403; 39%) neurological complaints.
Median follow-up was 6.6 years. The overall median survival was 4.8 months 
(95%CI 4.3-5.4). In total 984 patients (94%) died during follow-up with a median 
survival of 4.3 months (95%CI 3.8-4.9). Two-hundred-and-forty-three (23%) 
patients died within six weeks after starting treatment, whereas 179 (17%) patients 
survived for more than two years.
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Table 1. Population characteristics. SD: standard deviation.
Characteristic N (%)
Gender
   Male
   Female
542 (52)
501 (48)
Age (mean, years ± SD) 64.8 ± 12.5
Clinical profile
   Favorable
   Moderate
   Unfavorable
Location treated spinal metastases
   Cervical only
   Cervicothoracic
   Thoracic only
   Thoracolumbar
   Lumbar only
   Diffuse
Number spinal metastases
   One
   Two
   Three or more
Number extraspinal bone metastases
   None
   One or two
   Three or more
Visceral metastases
   Present
   Not present
Brain metastases
   Present
   Not present
Karnofsky performance status
   Normal (100-80%)
   Impaired (70-10%)
   Missing
Frankel classification
   No deficit (E)
   Minor motor or sensory deficit (D)
   Major motor or sensory deficit (A, B, C)
   Missing
312 (30)
296 (28)
435 (42)
40 (4)
121 (12)
256 (24)
275 (27)
309 (30)
42 (3)
326 (31)
191 (19)
526 (50)
370 (35)
287 (28)
386 (37)
380 (36)
663 (64)
71 (7)
972 (93)
387 (37)
607 (58)
49 (5)
518 (50)
403 (39)
112 (10)
10 (1)
 
The most prevalent primary tumors were breast cancer (n=299), lung cancer 
(n=255), prostate cancer (n=215), kidney cancer (n=60) and colon cancer (n=55) 
(table 2). 
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Table 2. Primary tumor, related survival and clinical profile. UCC: urothelial cell carcinoma. ACUP: 
adenocarcinoma of unknown primary. CI: confidence interval.
Primary tumor Number(%) Median survival (95%CI) Profile
Breast
Thyroid
Prostate
Kidney
Ovary
Osteosarcoma
Uterus sarcoma
Lung
Colon
UCC
ACUP
Esophagus 
Melanoma
Pancreaticobiliary
Ewing’s Sarcoma
Cervix
Endometrium
Stomach
Liver
Tongue
299 (29)
13 (1)
215 (21)
60 (6)
8 (1)
9 (1)
4 (<1)
250 (24)
55 (5)
27 (3)
22 (2)
20 (2)
17 (2)
11 (1)
10 (1)
7 (1)
5 (1)
4 (<1)
4 (<1)
3 (<1)
18.6 (14.9-22.2)
4.8 (0.0-24.9)
6.6 (5.2-8.1)
4.5 (2.6-6.4)
4.9 (2.3-7.6)
6.3 (0.0-12.6)
4.6 (0.0-10.0)
1.9 (1.5-2.4)
3.2 (1.8-4.5)
1.7 (0.9-2.6)
2.4 (0.9-3.8)
1.7 (0.1-3.3)
1.2 (0.5-1.8)
1.7 (1.2-2.2)
1.9 (0.3-3.5)
2.3 (0.0-5.7)
1.9 (0.9-3.0)
1.2 (0.2-2.3)
7.5 (0.0-15.8)
0.8 (0.7-0.8)
Favorable
Favorable
Moderate
Moderate
Moderate
Moderate
Moderate
Unfavorable
Unfavorable
Unfavorable
Unfavorable
Unfavorable
Unfavorable
Unfavorable
Unfavorable
Unfavorable
Unfavorable
Unfavorable
Unfavorable
Unfavorable
 
Thirty percent of all patients were classified as having a favorable clinical profile 
with a median survival of 18.6 months (95%CI 15.1-22.1), followed by 29% with 
a moderate profile and a median survival of 5.9 months (95%CI 4.8-7.0) and 41% 
with an unfavorable profile and a median survival of 2.2 months (95%CI 1.9-2.6) 
(figure 2).
Radiotherapy was the most commonly used primary treatment in a total of 997 
patients (95%). Only 46 patients (5%) underwent surgery. See table 3 for the 
radiotherapy regimens and surgical techniques used.
The DBMS database consisted of 342 SBM patients treated with radiotherapy. 
Median follow-up was 2.2 years and overall median survival was 8.9 months 
(95%CI 7.4-10.3). In total 258 patients (76%) died during follow-up. Further 
details of the patient population are published elsewhere4.
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Figure 2. Survival curves of clinical profiles.
 
Table 3. Treatment details.
Treatment N (%)
Overall
   Radiotherapy only
   Surgery and radiotherapy 
   Surgery only
997 (95)
39 (4)
7 (1)
Radiotherapy regimens
   1x8 Gy
   2x8 Gy
   6x4 Gy or 5x4 Gy
   Other – Total dose >24 Gy
445 (43)
169 (16)
322 (31)
100 (10)
Surgery
   Minimal invasive
   Limited decompression and fixation
   Extended decompression and fixation
10 (22)
23 (50)
13 (28)
 
Analysis of the entire cohort
Results of the univariate and multivariate analyses are detailed in table 4. The 
three clinical profiles (moderate HR1.6, 95%CI 1.3-2.1, p<0.001) (unfavorable 
HR3.5, 95%CI 2.9-4.4, p<0.001), the KPS (HR1.9, 95%CI 1.6-2.2, p<0.001) and 
the presence of visceral metastases (HR1.5, 95%CI 1.3-1.7, p<0.001) were shown 
to be of influence on survival. The Frankel classification, the number and location 
of the spinal metastases and the presence of brain and extraspinal bone metastases 
did not influence survival.
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Table 4. Results of the uni- and multivariate analyses. HR: hazard ratio. CI: confidence interval. C: cervical. 
CT: cervicothoracic. T: thoracic. TL: thoracolumbar. L: lumbar. D: diffuse.
Univariate log-rank test p-value
Clinical profile (Favorable/Moderate/Unfavorable)
Karnofsky (100-80/70-10)
Frankel classification (ABC/D/E)
Visceral metastases (Yes/No)
Brain metastases (Yes/No)   
Number spinal metastases (1/2/≥3)
Extra-spinal metastases (0/1/≥2)
Location spinal metastases (C/CT/T/TL/L/D)
<0.001
<0.001
<0.001
<0.001
0.012
0.983
0.093
0.836
Multivariate Cox-regression model HR 95%CI p-value
Clinical profile
   Favorable
   Moderate
   Unfavorable
Performance status
   Normal (100-80)
   Impaired (70-10)
Visceral metastases
   Not present
   Present
-
1.6
3.5
-
1.9
-
1.5
-
1.3-2.1
2.9-4.4
-
1.6-2.2
-
1.3-1.7
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
 
 
Table 5. Results of the uni- and multivariate analyses stratified for clinical profile. HR: hazard ratio. 
CI: confidence interval.
Univariate analysis Favorable
(n=312)
Moderate
(n=296)
Unfavorable
(n=435)
Performance status  
Visceral metastases
Brain metastases
Frankel classification 
Number spinal metastases
Bone metastases
Location spinal metastases
<0.001
<0.001
0.009
0.043
0.054
0.078
0.657
<0.001
0.086
0.482
0.757
0.469
0.120
0.196
<0.001
0.165
0.528
0.248
0.243
0.943
0.867
Cox-regression models HR 95% CI p-value
Model 1: Favorable profile
   Performance status  ≤70
   Visceral metastases present
   Brain metastases present
Model 2: Moderate profile
   Performance status  ≤70
Model 3: Unfavorable profile
   Performance status  ≤70
1.7
2.0
1.8
2.3
1.9
1.3-2.2
1.5-2.7
1.1-3.0
1.7-2.9
1.5-2.3
<0.001
<0.001
0.016
<0.001
<0.001
 
Analysis stratified for clinical profile
Results of the univariate and multivariate analyses for the three clinical profiles are 
illustrated in table 5. A poor KPS (HR 1.7, 95%CI 1.3-2.2, p<0.001), the presence 
of visceral metastases (HR 2.0, 95%CI 1.5-2.7, p<0.001) and the presence of brain 
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metastases (HR 1.8 95%CI 1.1-3.0, p=0.016) were shown to have an association 
with survival in the favorable profile. In the moderate and unfavorable profiles, 
only the KPS affected survival (HR 2.3. 95%CI 1.7-3.0, p<0.001) and (HR 1.9, 
95%CI 1.5-2.3, p<0.001), respectively. 
Training data set and validation data set
Based on the results of the three multivariate analyses, the cohort was divided into 
eight groups (figure 3A). By comparing the median survival of the groups, four 
final categories A, B, C and D were created (table 6). Patients in category A had 
a median overall survival of 31.2 months (95%CI 25.2-37.3) , compared to 15.4 
months (95%CI 11.9-18.2) for patients in category B, 4.8 months (95%CI 4.1-5.4) 
for patients in category C and 1.6 months (95%CI 1.4-1.9) for patients in category 
D (figure 3B and table 7). Harrell’s c-statistic was 0.71, when calculated based on 
the training data set.
Patients in category A of the validation data set had a median survival of 16.3 
months (95%CI 11.1-21.6), compared to 12.8 months (95%CI 9.5-16.0) for 
category B, 7.0 months (95%CI 5.1-9.0) for category C and 3.6 months (95%CI 2.6-
4.6) for category D (figure 3C and table 7). The c-statistic based on the validation 
data set was 0.69.
Table 6. Groups based on multivariate analysis
Clinical Profile KPS VM/BRM MOS (95%CI) N (%) Category
Favorable
Favorable
Favorable
Favorable
100-80
100-80
70-10
70-10
No
Yes
No
Yes
31.2 (25.2-37.3)
14.0 (6.8-21.1)
18.6 (16.0-21.1)
4.8 (2.3-7.3)
116 (12)
42 (4)
87 (9)
52 (5)
A
B
B
C
Moderate
Moderate
100-80
70-10
N/A
N/A
12.5 (6.5-18.5)
4.8 (4.0-5.6)
97 (10)
190 (19)
B
C
Unfavorable
Unfavorable
100-80
70-10
N/A
N/A
4.5 (3.1-5.8)
1.6 (1.4-1.9)
132 (13)
278 (28)
C
D
KPS: Karnofsky Performance Status. VM/BRM: visceral and/or brain metastases. MOS: median overall 
survival.
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Table 7. Survival times training and validation data sets. CI: Confidence interval. HR: Hazard ratio. 
MOS: Median overall survival
Category MOS (95%CI) N (%) HR 95% CI p-value
Training data set
A
B
C
D
Validation data set
A
B
C
D
31.2 (25.2-37.3)
15.4 (11.9-18.2)
4.8 (4.1-5.4)
1.6 (1.4-1.9)
16.3 (11.1-21.6)
12.8 (9.5-16.0)
7.0 (5.1-9.0)
3.6 (2.6-4.6) 
116 (12)
226 (23)
374 (37)
278 (28)
64 (19)
111 (33)
91 (27)
73 (21)
-
1.8
4.4
9.3
-
1.5
2.8
6.0
-
1.4-2.3
3.5-5.6
7.2-12.1
-
1.0-2.2
1.9-4.1
3.9-9.2
<0.001
<0.001
<0.001
<0.001
<0.001
0.029
<0.001
<0.001
Figure 3A. Eight categories prior to merging.
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Figure 3B. Stratification model after merging.
Figure 3C. Stratification model applied to DBMS database.
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DISCUSSION
In this retrospective study of 1043 patients treated for symptomatic SBM it is 
shown that the clinical profile of the primary tumor, performance status and – in 
the subgroup of a favorable clinical profile only – the presence of visceral and 
brain metastases are associated with survival. Other prognostic factors such as the 
presence of extraspinal bone metastases, number and location of spinal metastases 
and neurological functioning did not show a significant effect on survival.
The most important limitation of this study is its retrospective design. Due to the 
fact that all patients were treated in a single institution, clinical information was 
readily available, including radiology reports. However, this does not rule out 
the possibility of inaccuracy of the source data. Furthermore, no SBM-specific 
treatment protocols existed, exemplified by the fact that the landmark study by 
Patchell et al.2 resulted in more surgical interventions being performed in the 
period after publication. However, as this study analyzes survival only and therapy 
for SBM is not directly aimed at prolonging survival, it is unlikely that our results are 
influenced by this change in therapeutic approach. It is possible that the presence 
of brain metastases is underrepresented in this study population, as whole-brain 
scans were not routinely performed, contrary to thoracic and abdominal scans. As 
a result, most of the patients with brain metastases had symptomatic lesions. It is 
unclear whether asymptomatic brain metastases have the same predictive value in 
this specific patient population. Lastly, in our institution treatment for SBM only 
takes place in symptomatic patients and only patients treated locally for their SBM 
by means of surgery or radiotherapy were included. As a consequence, patients 
with symptomatic SBM that received only supportive care no are not represented 
in this study.
In contrast to the previous study by our group – which was based on a prospective 
database with only radiotherapy patients - patients with a cervical located SBM 
were not excluded, nor were patients with renal cell carcinoma, leading to better 
generalizability of the data. Because the prospective DBMS database was closed 
after an inclusion period of 2.5 years, median follow-up times are distinctly 
different. Survival times in category A are therefore limited. Since the DBMS 
inclusion criteria were stricter and contained more patients with a favorable 
clinical profile and fewer with an unfavorable profile, median survival times were 
57647 Laurens Bollen.indd   62 05-08-19   09:44
PREDICTIVE MODEL
63
IV
better than in the current database. However, as a nearly identical c-score shows, 
the presented model is still capable of stratification based on the identified risk 
factors.
As has been established in literature, primary tumor type – in this study 
represented by clinical profile – is shown to be the factor of greatest influence on 
survival in patients with symptomatic SBM21. This means that an accurate and 
up-to-date tumor classification is essential for prognostication. The positive effect 
of new treatments such as anti-VEGF therapy will mean that in the near future 
survival with symptomatic SBM may increase considerably for certain tumors22. 
Also, it is unclear whether there is a difference in survival for patients with SBM 
from different subtypes of the same primary cancer, as is the case in breast cancer 
with estrogen, progesterone and HER2 interactions23. These topics should be the 
subject of further SBM-specific studies. 
A poor performance status nearly doubles the risk of death in all three clinical 
profiles and is the second most important variable to assess in patients with SBM. 
Even though the Karnofsky score is a subjective score and highly susceptible to 
changes in neurological functioning, it remains an effective tool to quickly assess 
a patient’s general condition. The use of a performance related score as risk factor 
when estimating survival is also superior when compared to age, as age only gives 
an indirect measure of a patients’ functional status. Contrary to the Tokuhashi and 
Van der Linden models, the KPS was divided into two categories instead of three 
in order to facilitate clinical decision-making. 
To the authors’ best knowledge, this is the first study to describe that the effect of 
visceral and brain metastases differs per primary tumor category. Overall, there 
was no influence of brain metastases and the effect of visceral metastases was 
only marginal. However, after stratification for the clinical profile, a statistically 
significant effect on survival for visceral and brain metastases was found in the 
favorable category only. The presence of brain or visceral metastases were not 
associated with survival of patients in both the moderate and unfavorable profiles, 
obviating the need for additional radiologic examinations in these groups when 
estimating survival. Most likely, this is due to the fact that survival in these two 
categories already is very short based on the primary tumor and the effect of 
visceral or brain metastases therefore becomes negligible.
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Even though neurological status is one of the most important factors to consider 
when deciding on treatment, the presence of neurological deficit at the start of 
treatment does not directly influence survival in any of the three clinical profiles 
described in this study. Rades et al. have shown that the time of developing motor 
deficits is the most important factor predicting improvement of neurological 
functioning after treatment24. Neurologic status should therefore be viewed as an 
indication for treatment, rather than a predictive factor when estimating survival. 
Especially in the case of sudden paraplegia due to spinal cord compression, swift 
and decisive treatment is far more important than estimation of survival, as the 
possible benefits of treatment in terms of quality of life far outweigh the possible 
risks in terms of a short remaining lifespan. When assessing neurological deficit in 
patients with SBM, the Frankel classification might not be the most suitable tool, 
as it was originally designed for categorizing spinal cord injury only. Neurological 
symptoms caused by nerve root compression or compression of the cauda equina 
are not covered, necessitating the development of a SBM-specific classification for 
describing neurological deficit. 
Figure 4. Flowchart for stratification.
 
Even though the number and location of SBM influence treatment options such 
as possibilities of surgical fixation and range of radiation fields, they did not show 
a significant effect on survival. Sixty-nine percent of all studied patients had more 
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than one confirmed spinal metastasis and it is not unlikely that a large proportion 
of patients classified as having a solitary metastasis in fact have occult lesions 
not yet detected25. Lastly, the presence of extraspinal bone metastases was not 
associated with survival. 
New model
A flowchart was created to guide the stratification of patients with symptomatic 
SBM (figure 4). Based on a maximum of three easy to obtain variables, patients 
are classified into one of four categories (A-D), each with a distinctly different 
estimated survival time. The effect of this approach is particularly striking in 
patients with a favorable clinical profile: by assessing two variables the median 
survival is split from 18.6 months (95%CI 15.1-22.1) overall, down to 4.8 months 
(95%CI 2.3-7.3) and up to 31.2 months (95%CI 25.2-37.3) (table 7).
Harrell’s c-statistic was almost identical when the new model was applied to an 
external database, indicating good reproducibility of our results. The current 
values of 0.71 and 0.69 indicate a good predictive value of the model and with 
a more accurate classification of primary cancers into one of the three clinical 
profiles, the value of c should rise even further.
This large data collection provides a better understanding of how risk factors 
interact when stratified for primary tumor. It is shown that clinical profile 
and performance status have a strong impact on survival in all patients with 
symptomatic SBM. The presence of visceral and/or brain metastases is associated 
with a shortened survival only in patients with a favorable clinical profile.
The model presented in this study can be used as a simple stratification tool in 
patients presenting with symptomatic SBM. Also, it can be used in future studies 
comparing efficacy of radiotherapy regimens and various types of surgical 
intervention, as well as studies into the effects on quality of life of different 
treatment modalities.
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ABSTRACT
Background. To aid in therapy selection for patients with spinal bone metastases 
(SBM), predictive models have been developed. These models consider SBM from 
breast cancer a positive predictive factor, but do not take phenotypes based on 
estrogen (ER), progesterone (PR) and human epidermal growth factor 2 (HER2) 
receptors into account. The aim of this study was to ascertain whether receptors 
are associated with survival, when the disease has progressed up to SBM.
Methods. All patients who were treated for SBM from breast cancer between 2005 
and 2012 were included in this international multi-center retrospective study 
(n=110). Reports were reviewed for ER, PR and HER2 status and subsequently 
subdivided into one of four categories; luminal A, luminal B, HER2 and triple 
negative. Survival time was calculated as the difference between start of treatment 
for SBM and date of death. Analysis was performed using the Kaplan-Meier 
method and log-rank tests.
Results. Median follow-up was 3.7 years. Survival times in the luminal B and 
HER2 categories were not significantly different to the luminal A category and 
were joined into a single receptor positive category. Eighty-five patients (77%) 
had a receptor positive phenotype and 25 (23%) had a triple negative phenotype. 
Median survival time was 22.5 months (95%CI 18.0-26.9) for the receptor 
positive category and 6.7 months (95%CI 2.4-10.9) for the triple negative category 
(p<0.001).
Conclusions. Patients with SBM from breast cancer with a triple negative phenotype 
have a shorter survival time than patients with a receptor positive phenotype. 
Models estimating survival should be adjusted accordingly.
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INTRODUCTION
The treatment of patients with symptomatic spinal bone metastases (SBM) has 
made considerable progress over the past two decades. Even though radiotherapy 
remains the cornerstone of treatment, surgical interventions are being increasingly 
used, ranging from minimally invasive surgery to total en-bloc spondylectomy. 
Patients with SBM generally have a short remaining life span, making risk of 
overtreatment a common concern. Therefore, extent and type of treatment should 
not only depend on a patient’s symptoms, but also on expected survival.  Several 
survival prediction models have been developed to aid in clinical decision making 
and whilst they differ in approach, it is accepted that the primary tumor causing 
the SBM is the strongest predictor of survival1,2. Patients with symptomatic SBM 
from breast cancer tend to live longer than patients with SBM from, for instance, 
prostate or lung cancer3,4. This is reflected in all predictive models, where breast 
cancer is considered a favorable prognostic factor, as opposed to other primary 
cancers5-9.
Based on estrogen receptor status (ER), progesterone receptor status (PR) and 
human epidermal growth factor receptor 2 status (HER2), several molecular 
phenotypes of breast cancer can be distinguished10,11. It has been established that 
these phenotypes are predictive of survival from the time of diagnosis of the 
primary tumor12,13, however, it is unclear whether this effect remains when the 
disease has progressed up to the point of symptomatic SBM. If so, the manner in 
which the aforementioned predictive models stratify patients based on primary 
tumors needs to be adjusted, distinguishing between different breast cancer 
phenotypes.
The aim of the present study was to ascertain whether breast cancer molecular 
phenotypes are associated with survival of patients presenting with symptomatic 
SBM and to provide guidelines for improvement of the existing predictive models, 
if necessary.
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METHODS
In this international multicenter retrospective cohort study, all consecutive breast 
cancer patients presenting with symptomatic SBM between January 2005 and 
December 2012 at tertiary referral centers in Leiden, Graz, and Aarhus were 
included. The primary data sources were the patient’s clinical files, pathology 
reports and admission forms. ER, PR and HER2 information was obtained from 
reports at the time of diagnosis of the primary tumor. Due to the fact that the process 
of decalcification can influence the results of the receptor status determination, 
only information derived from material of the primary tumor was entered into 
the study. Receptor information derived from the metastasis was disregarded. 
In all three participating centers, tumors were considered positive for ER or PR 
when ≥10% of the tumor cells displayed nuclear staining. Initial screening for 
HER2 was performed using immunohistochemistry. When results were equivocal 
(weakly positive; score 2+) additional molecular testing was performed using in 
situ hybridization. In Leiden, chromogenic in situ hybridization (CISH) was used, 
whereas in Graz and Aarhus fluorescent in situ hybridization (FISH) was used. All 
laboratories participated in quality assurance programs during the study period.
Based on the ER, PR and HER2 expression, tumors were further subdivided into 
four categories; luminal A, luminal B, HER2 and triple negative. The luminal A 
subtype is ER positive and/or PR positive without HER2 overexpression. The 
luminal B subtype is ER positive and/or PR positive with HER2 overexpression. 
The HER2 subtype is ER and PR negative, with HER2 overexpression. Finally, the 
triple negative subtype is negative for all three receptors. To avoid confounding 
of our results based on the availability of systemic treatment options, 2005 was 
chosen as the starting year of this study. At this time, the testing for HER2 status 
was common practice and guidelines in all participating centers had implemented 
the routine use of agents such as trastuzumab in both adjuvant and palliative 
settings.
Statistical analysis
Survival time was calculated as the difference between start of treatment for the 
spinal metastasis and date of death or last follow-up moment recorded. Survival 
curves were estimated by using Kaplan-Meier method. Follow-up was assessed 
by employing the reverse Kaplan-Meier method14. Cox proportional hazard 
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models were used to assess the effect of the molecular phenotypes on survival. 
Survival curves were compared using log-rank tests. Harrell’s C-statistic was used 
as a measure of the predictive accuracy of the model before and after adjustment. 
The C-statistic estimates the probability of concordance between predicted and 
observed responses15. A p-value of <0.05 was considered statistically significant. 
All analyses were performed using SPSS 20.0, Armonk NY, IBM Corp.
 
RESULTS
Table 1 summarizes the characteristics of the 111 patients studied, of whom 110 
(99%) were female and one (1%) was male. The mean age at the start of treatment 
for the spinal metastasis was 59.9 years (SD ± 13.9 years).The symptomatic SBM 
were most commonly located in the thoracic (n=34, 31%) part of the spine. 
Primary treatment of the spinal metastasis consisted either of radiotherapy (n=69, 
62%), surgery (n=21, 19%) or systemic therapy only (n=21, 19%). Patients were 
classified as luminal A (n=67, 60%), luminal B (n=9, 8%), HER2 (n=11, 10%) and 
triple negative (n=24, 22%).
Median follow-up was 3.2 years (minimum 0.6, maximum 5.5 years) and there was 
no loss to follow-up. The overall median survival was 18.0 months (95%CI 12.7-
23.2) and there was no significant difference in median survival times between the 
participating centers (p=0.529) (table 2).  In total 82 patients (74%) died during 
follow-up.
Survival analysis showed that median survival times in the luminal A, luminal B 
and HER2 categories were not significantly different, whereas the median survival 
time in the triple negative category was shorter (figure 1A and table 2). Due to 
the fact that there were few patients in the luminal B and HER2 categories, these 
were added to the luminal A group, creating a new category ‘receptor positive’ as 
opposed to the triple negative category.
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Table 1. Patient characteristics. SD: standard deviation.
Characteristic N (%)
Gender
   Female
   Male
Age (mean, years ± SD)
Location treated spinal metastases
   Cervical only
   Cervicothoracic
   Thoracic only
   Thoracolumbar
   Lumbar only
   Diffuse
Visceral and/or brain metastases
   Present
   Not present
Karnofsky performance status
   Normal (100-80%)
   Impaired (70-10%)
   Missing
Initial SBM treatment
   Radiotherapy
   Surgery
   Systemic / Palliative
Molecular phenotype
   Luminal A
   Luminal B
   HER2
   Triple negative
110 (99)
1 (1)
59.9 ± 13.9
None
12 (11)
34 (31)
25 (22)
17 (15)
23 (21)
56 (50)
55 (50)
58 (52)
52 (47)
1 (1)
69 (62)
21 (19)
21 (19)
67 (60)
9 (8)
11 (10)
24 (22)
 
Table 2. Survival data per hospital and phenotype. MOS: median overall survival. P-values refer to overall 
log-rank comparison.
Variable N (%) MOS (95%CI) p-value
Hospital
   Leiden
   Graz
   Aarhus
Molecular phenotype 
   Luminal A
   Luminal B
   HER2
   Triple negative
Receptor Status
   Receptor positive
   Triple negative
61 (55)
39 (35)
11 (10)
67 (60)
9 (8)
11 (10)
24 (22)
87 (78)
24 (22)
18.0 (9.5-26.4)
16.6 (8.8-24.4)
14.7 (3.1-26.4)
22.5 (17.9-27.0)
26.9 (9.1-44.7)
20.9 (1.1-40.8)
5.5 (2.0-9.0)
23.4 (19.0-27.8)
5.5 (2.0-9.0)
0.529
<0.001
<0.001
 
The subsequent survival analysis showed a median survival time of 23.4 months 
(95%CI 19.0-27.8) for the receptor positive category and 5.5 months (95%CI 
2.0-9.0) for the triple negative category (p<0.001) (figure 1B and table 2). The 
corresponding hazard ratio was 3.6 (95%CI 2.1-5.9, p<0.001). The median time to 
development of symptomatic SBM from diagnosis of the primary tumor was 11.0 
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months (95%CI 2.0-20.0) in the triple negative category and 21.1 months (95%CI 
14.0-28.2) in the receptor positive category (p=0.005).
Figure 1A. Survival curves of all four phenotypes
Figure 1B. Survival curves after merging
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To illustrate the effects of discerning between receptor positive and triple negative 
breast cancer, the cohort was stratified into three categories according to a 
previously published predictive model9, both before and after adjusting the primary 
tumor classification. Before adjustment, all breast cancer patients were considered 
to have a ‘favorable clinical profile’. The current results, however, suggest that triple 
negative breast cancer should be considered as having a ‘moderate clinical profile’, 
since a median survival of 5.5 months is in line with survival times described in 
this category. Receptor positive breast cancer remains in the ‘favorable’ category. 
The number of patients in category A decreased from 32 (29%) to 27 (25%) 
and the median survival time has risen from 31.2 months (95%CI 14.6-47.9) to 
39.6 months (95%CI 19.2-60.0). Patients with a triple negative phenotype have 
been assigned to categories B and C, decreasing median survival times in those 
categories slightly (table 3).The C-statistic before the adjustment was 0.61 and after 
the adjustment 0.64, suggesting an improvement in the accuracy of the model.
 
Table 3. Median survival times before and after model adjustment for molecular phenotype. MOS: median 
overall survival. HR: hazard ratio. CI: confidence interval. 
Predictive Category N (%) MOS (95%CI) HR 95%CI p-value
Before adjustment
   A
   B
   C
   D
After adjustment
   A
   B
   C
   D
32 (29)
48 (44)
30 (27)
None
27 (25)
51 (46)
32 (29)
None
31.2 (14.6-47.9)
15.9 (8.7-23.1)
9.8 (7.6-12.0)
N/A
39.6 (19.2-60.0)
14.7 (9.9-19.5)
9.3 (7.1-11.5)
N/A
-
1.8
2.7
N/A
-
2.5
3.8
N/A
-
1.0-3.1
1.5-4.9
N/A
-
1.3-4.7
1.9-7.3
N/A
0.007
0.046
0.002
N/A
0.001
0.004
<0.001
N/A
DISCUSSION
In this international multi-center retrospective study of 111 patients treated for 
symptomatic SBM caused by breast cancer, it is shown that, even though the 
disease has progressed up to end stage disease, patients with a triple negative 
phenotype have a much shorter median survival time (5.5 months, 95%CI 2.0-9.0) 
than patients with a receptor positive phenotype (23.4 months, 95%CI 19.0-27.8). 
This suggests that models estimating survival in patients with symptomatic SBM 
should at least differentiate between these two types of breast cancer. 
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Even though in general patients with symptomatic SBM from breast cancer have 
a relatively long survival, the limited availability of systemic treatment options in 
patients with a triple negative phenotype results in a shorter survival. Predictive 
models based on previous studies overestimated survival in these patients, 
leading to overtreatment. The effect of correcting for molecular phenotypes was 
confirmed when a previously published survival prediction model was adjusted 
for the current findings, resulting in an improvement of the accuracy (table 3 and 
figure 2). A precise model can be a useful tool for clinicians. Extensive surgical 
treatment and long-course radiotherapy regimens could be avoided in patients 
with a short expected survival and in patients with a longer expected survival 
extent of treatment could be increased, if needed.
The most important limitation of this study is its retrospective design. However, 
since the endpoint was death and the only clinical information gathered was 
derived from pathology reports, the design is not expected to have a large impact 
on the quality of our results. Also, receptor status was assessed in different 
laboratories and by different pathologists. HER2 immunohistochemistry can be 
difficult to interpret, however, in all three institutes equivocal cases were subjected 
to molecular testing using in situ hybridization. The distribution of patients over 
the four categories was slightly different when compared to larger studies16,17. 
The luminal B category was underrepresented and the luminal A category was 
overrepresented in this study. However, since the luminal B and HER2 categories 
contained few patients and were joined with the luminal A category the overall 
effect on the survival data was negligible. This means that a statement on the 
exact survival times in the luminal B and HER2 categories cannot be made based 
on small sample size. From a clinical perspective however, we believe it is more 
relevant to identify patients with a short survival in order to avoid overtreatment, 
than to give an exact estimation of survival for patients that have an expected 
survival of more than a year.
A previously published study on SBM from breast cancer investigated the role 
of ER and PR status on survival18 and found that patients negative for ER had a 
decreased survival when compared to patients with a positive ER status. As this 
study was conducted before the onset of HER2 testing, the effects of this receptor 
were not considered. A study conducted by Rades et al.19 examined the effects of 
several other risk factors, such as performance status and the presence of visceral 
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metastases. Based on these results a predictive model specifically for patients with 
SBM from breast cancer was created, but unfortunately the authors did not analyze 
the effects of receptor status on survival. 
In conclusion, in this study it is shown that patients with a triple negative phenotype 
have a much shorter survival than patients with a receptor positive phenotype. 
The data presented in this study can guide the adjustment and development of 
models estimating survival in patients with SBM, increasing predictive accuracy 
and reducing the risk of overtreatment. 
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ABSTRACT
Background. Models to aid in the decision making process for the treatment of 
spinal bone metastases (SBM) have been developed by Tomita, Tokuhashi, Van 
der Linden, Bauer, Rades and Bollen. The aim of this study was to assess the 
predictive accuracy of these six models designed to estimate survival of patients 
suffering from SBM.
Methods. All patients who were treated for SBM between 2000 and 2010 were 
included in this international multi-center retrospective study (n=1379). Medical 
records were reviewed for all items needed to employ the models. Survival time was 
calculated as the difference between start of treatment for SBM and date of death. 
Survival curves were estimated using the Kaplan-Meier method and accuracy was 
assessed with the c-statistic. Survival rates of the worst prognostic groups were 
evaluated at four months.
Results. Median follow-up was 6.7 years (95%CI 5.6-7.7) with a minimum of 2.3 
years and a maximum of 12.3 years. The overall median survival was 5.1 months 
(95%CI 4.6-5.6). The most common primary tumors were breast (n=388, 28%), 
lung (n=318, 23%) and prostate cancer (n=259, 19%). The Tokuhashi, Bauer, 
Tomita and Van der Linden models performed similar with a c-statistic of 0.64-0.66 
and a 4-month accuracy of 62-65%. The Rades model (c-statistic 0.44) and Bollen 
model (c-statistic 0.70) had a 4-month accuracy of 69% and 75%, respectively.
Conclusion. The Bollen model performs better than the other models. However, 
improvements are still warranted to increase the accuracy.
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INTRODUCTION
Prediction of survival has become an integral part of selecting the appropriate 
treatment for patients suffering from symptomatic spinal bone metastases (SBM). 
Depending on the symptoms, patients with a short expected survival are most likely 
to benefit from short radiotherapy regimens, best supportive care or minimally 
invasive surgery. Patients with a relatively long expected survival will most likely 
benefit from high dose radiotherapy or – in the case of radioresistant tumors and 
biomechanical instability – more extensive surgical interventions. Several studies 
have shown that the estimation of survival by clinicians in terminally ill patients 
is inaccurate and have suggested the use of prognostication models in order to 
prevent exposure of patients to unnecessarily extensive treatments1-3. 
Models to aid in the decision making process have been developed by Tokuhashi, 
Bauer – later modified by Leithner – Tomita, Van der Linden, Rades and Bollen4-10. 
These models make use of a combination of different risk factors to estimate the 
survival of individual patients. Several smaller studies have been undertaken 
to assess the predictive value of some of the models6,11-13, however, a large 
international validation study assessing all the models simultaneously has not yet 
been performed. 
The aim of this study was to assess the validity and predictive accuracy of six 
models designed to estimate survival in a large cohort of patients with spinal bone 
metastases.
 
MATERIALS AND METHODS
In this international multicenter retrospective cohort study, all patients presenting 
with symptomatic SBM at two tertiary referral centers in Leiden, the Netherlands 
and Graz, Austria between January 2000 and December 2010 were included. 
Patients were identified through database searches linking treatment and diagnostic 
codes and through database searches based on surgical coding. Information on 
date of death was obtained from medical records or by contacting the general 
practitioner or the civil registry office.
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The primary data sources were the patient’s clinical files, radiology reports and 
admission forms. Baseline variables obtained before start of treatment were 
gender, age, primary tumor, location and number of SBM, the presence of 
visceral and/or brain metastases, the presence of extraspinal bone metastases, 
pretreatment functioning according to the Karnofsky performance status14 (KPS) 
and neurological functioning according to the Frankel classification15. The Eastern 
Cooperative Oncology Group (ECOG) performance status16 was obtained based 
on the KPS values. Time to development of SBM was defined as the interval from 
primary cancer diagnosis to the diagnosis of SBM4. If required for a specific scoring 
system, primary tumors were classified as slow, moderate or rapid growing5,6,11. All 
variables were further subdivided according to the instructions of each predictive 
model, resulting in different classifications for the same variable. 
During the creation of the current database, visceral metastases were scored 
as either being present or not present. The models of Tomita and Tokuhashi 
models further distinguish visceral metastases as either being removable or not 
removable. In our analysis, if visceral metastases were present, they were scored as 
‘not removable’. Also, the model of Rades scores the time to development of motor 
deficits. Retrospectively, this variable could not accurately be obtained from the 
medical records used to create this database. Therefore, the maximum number 
of points in the model was reduced from 25 to 21 and the minimum from 6 to 5. 
The cutoff scores for the predictive groups were changed accordingly. The Bollen 
model was created based on a large percentage of patients also included in this 
study. Therefore, an additional analysis based on external data only was conducted 
for this model.
Statistical analysis
Survival time was calculated as the time between start of treatment for the spinal 
metastasis and date of death or latest follow-up. Survival curves were estimated by 
using the Kaplan-Meier method and were compared using log-rank tests. Follow-up 
was assessed by employing the reverse Kaplan-Meier method17. Hazard ratios were 
estimated by using Cox proportional hazard models. All multivariate models were 
corrected for differences in survival between the participating centers. Harrell’s 
c-statistic was used to assess the predictive power of each model. It estimates 
the probability of concordance between predicted and observed responses, with 
a value of 1.0 being perfect agreement18. For each model, survival rates of the 
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predictive group with the lowest expected survival were assessed at four and six 
months. Survival rates of the predictive groups with the highest expected survival 
were assessed at one and two years. A p-value of <0.05 was considered statistically 
significant. All analyses were performed using SPSS 20.0, Armonk NY, IBM Corp.
 
RESULTS
Table 1 summarizes the characteristics of the 1379 patients studied. Fifty-two 
percent were male and at baseline the mean age was 64.6 ± 12.4 years. The SBM 
were most commonly located in the thoracic part of the spine (n=376, 27%) and 
most patients had three or more SBM (n=730, 53%). Extraspinal bone metastases 
were found in 913 patients (66%) and visceral or brain metastases were found in 
611 patients (44%). The majority of patients had no (n=746, 54%), or only minor 
(n=464, 34%) neurological deficit. Treatment consisted of radiotherapy in 1141 
patients (83%) and 109 patients (8%) underwent a combination of surgery and 
radiotherapy. Thirty-three patients (2%) underwent only surgery and 96 patients 
(7%) had conservative treatment. The most prevalent primary tumors were breast 
Figure 1. Overall survival
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cancer (n=388, 28%), lung cancer (n=318, 23%), prostate cancer (n=259, 19%), 
kidney cancer (n=90, 7%) and colon cancer (n=73, 5%). The remaining 18% 
consisted of 16 different primary tumors (table 2).
Table 1. Patient characteristics. SD: standard deviation.
Characteristic N (%)
Sex
   Male
   Female
Age (years, mean ± SD)
Location treated spinal metastasis
   Cervical
   Cervicothoracic
   Thoracic
   Thoracolumbar
   Lumbar
   Diffuse
Number spinal metastases
   One
   Two
   Three or more
Number extraspinal bone metastases
   None
   One or two
   Three or more
Karnofsky performance status     
   100
   80-90
   60-70
   40-50
   10-30
   Missing
Visceral/Brain metastases
   Present
   Not present
Frankel score
   A
   B
   C
   D
   E
   Missing
Treatment
   Radiotherapy
   Surgery
   Radiotherapy and surgery
   Palliative/conservative 
Hospital
   Leiden
   Graz
ECOG performance status
   0
   1
   2
   3
   4
   Missing
718 (52)
661 (48)
64.6 ± 12.4
53 (4)
63 (5)
376 (27)
351 (25)
332 (24)
204 (15)
415 (30)
234 (17)
730 (53)
466 (44)
336 (24)
577 (42)
22 (2)
518 (37)
466 (34)
294 (21)
30 (2)
49 (4)
611 (44)
768 (56)
8 (<1)
8 (<1)
143 (10)
464 (34)
746 (55)
10 (<1)
1141(83)
33 (2)
109 (8)  
96 (7) 
1043 (76)
336 (24)
57647 Laurens Bollen.indd   86 05-08-19   09:44
SCORING SYSTEMS
87
VI
Table 2. Primary tumors and median survival times. ACUP: adenocarcinoma of unknown primary. CI: 
confidence interval.
Primary N (%) Median survival (95%CI)
Breast
Lung
Prostate
Kidney
Colon
Urothelial cell carcinoma
ACUP
Melanoma
Pancreaticobiliary
Esophagus
Thyroid
Stomach
Hepatocellular carcinoma
Ewing sarcoma
Osteosarcoma
Ovary
Cervix
Uterus sarcoma
Endometrium
Tongue
Liposarcoma
388 (28)
318 (23)
259 (19)
90 (7)
73 (5)
36 (3)
31 (2)
28 (2)
28 (2)
27 (2)
15 (1)
14 (1)
13 (<1)
12 (<1)
9 (<1)
9 (<1)
8 (<1)
8 (<1)
6 (<1)
4 (<1)
3 (<1)
18.6 (15.8-21.4)
2.0 (1.6-2.4)
7.4 (5.9-9.0)
7.8 (4.2-11.3)
3.1 (2.3-3.9)
1.7 (0.9-2.5)
2.8 (1.9-3.6)
1.5 (0.2-2.8)
2.5 (1.7-3.3)
2.1 (1.1-3.0)
7.3 (0.0-22.3)
1.4 (0.0-3.4)
4.8 (3.9-5.7)
2.7 (0.3-5.1)
6.3 (0.0-12.6)
5.4 (4.1-6.6)
2.3 (0.0-7.7)
7.2 (0.8-13.5)
1.9 (0.0-17.7)
0.8 (0.0-2.8)
13.4 (0.0-34.7)
 
Median follow-up from start of treatment was 6.7 years (95%CI 5.6-7.7) with a 
minimum of 2.3 years and a maximum of 12.3 years. Six patients moved abroad 
after treatment and were lost to follow-up. The overall median survival was 5.1 
months (95%CI 4.6-5.6) (figure 1). A total of 1318 patients (96%) died during 
follow-up. Within two months after starting treatment, 379 patients (27%) died, 
whereas 257 patients (19%) survived for more than two years.
Multivariate analysis of each separate model showed that the primary tumor, 
performance status, the presence of visceral metastases and the time to development 
of SBM were associated with survival. Neurological functioning or ambulatory 
status, the number of spinal bone metastases and the number of extraspinal bone 
metastases were not significantly associated with survival in any of the models 
(table 3). 
The median survival times and corresponding hazard ratios for each subgroup of 
all six models are shown in table 4. Even though all models are able to distinguish 
between short and long expected survival, the number of patients in each category 
differs greatly. Model based survival curves are shown in figures 2A-2F. 
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Table 3. Multivariate analysis of the variables for survival prediction as presented in the six models.
Tokuhashi HR 95%CI p-value
Primary tumor
Performance status
Visceral metastases
Other bone metastases
Spinal bone metastases
Neurologic functioning
1.3
1.8
1.2
-
-
-
1.2-1.3
1.6-1.9
1.1-1.3
-
-
-
<0.001
<0.001
<0.001
n.s.
n.s.
n.s.
Bauer HR 95%CI p-value
Primary tumor
Visceral metastases
Bone metastases
2.0
1.4
-
1.8-2.2
1.4-1.8
-
<0.001
<0.001
n.s.
Tomita HR 95%CI p-value
Primary tumor
Visceral metastases
Bone metastases
1.5
1.1
-
1.4-1.6
1.0-1.1
-
<0.001
<0.001
n.s.
Van der Linden HR 95%CI p-value
Primary tumor
Performance status
Visceral metastases
1.4
1.7
1.4
1.3-1.5
1.6-1.9
1.3-1.6
<0.001
<0.001
<0.001
Rades HR 95%CI p-value
Primary tumor
Performance status
Visceral metastases
Interval to SBM
Other bone metastases
Ambulatory status
1.6
1.2
1.1
1.2
-
-
1.5-1.7
1.1-1.2
1.1-1.2
1.1-1.3
-
-
<0.001
<0.001
<0.001
<0.001
n.s.
n.s.
Bollen  HR 95%CI p-value
Primary tumor
Performance status
Visceral metastases
1.9
2.0
1.4
1.7-2.0
1.8-2.2
1.1-1.6
<0.001
<0.001
<0.001
HR: hazard ratio. CI: confidence interval. NS: not significant.
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Table 4. Results survival analysis and multivariate analysis for survival prediction categories. MOS: median 
overall survival. CI: confidence interval. HR: hazard ratio.
Tokuhashi N (%) MOS, months (95%CI) HR (95%CI) p-value
Excisional
Palliative
No surgery
259 (20)
493 (37)
573 (43)
17.9 (12.8-22.9)
8.4 (7.0-9.8)
2.7 (2.4-3.0)
-
1.6 (1.4-1.9)
3.5 (3.0-4.2)
<0.001
<0.001
<0.001
Bauer N (%) MOS, months (95%CI) HR (95%CI) p-value
Local control
Palliative
Supportive care
344 (25)
546 (40)
489 (35)
18.7 (15.8-21.7)
5.9 (4.9-6.9)
2.5 (2.2-2.8)
-
2.1 (1.8-2.4)
3.8 (3.3-4.5)
<0.001
<0.001
<0.001
Tomita N (%) MOS, months (95%CI) HR (95%CI) p-value
Long-term
Middle-term
Short-term
Terminal
299 (22)
277 (20)
410 (30)
393 (28)
21.8 (18.6-25.0)
5.9 (4.7-7.1)
4.9 (3.8-5.9)
2.5 (2.2-2.8)
-
2.2 (1.9-2.7)
2.7 (2.3-3.1)
4.3 (3.7-5.1)
<0.001
<0.001
<0.001
<0.001
Van der Linden N (%) MOS, months (95%CI) HR (95%CI) p-value
A
B
C
146 (11)
559 (42)
625 (47)
29.8 (23.1-36.5)
9.7 (8.2-11.1)
2.5 (2.3-2.7)
-
2.3 (1.9-2.8)
5.8 (4.7-7.2)
<0.001
<0.001
<0.001
Rades N (%) MOS, months (95%CI) HR (95%CI) p-value
Extensive
Palliative
1111 (84)
216 (16)
6.8 (6.1-7.6)
1.8 (1.4-2.3)
-
2.7 (2.3-3.1)
<0.001
<0.001
Bollen N (%) MOS, months (95%CI) HR (95%CI) p-value
A
B
C
D
149 (11)
318 (24)
489 (37)
374 (28)
29.8 (22.7-36.9)
16.5 (14.0-19.0)
4.9 (4.4-5.4)
1.7 (1.4-2.0)
-
1.8 (1.4-2.2)
4.1 (3.2-5.1)
9.2 (7.3-11.4)
<0.001
<0.001
<0.001
<0.001
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Figure 2a-2f. Model based survival curves.
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Table 5 shows the c-statistic for each model, and the percentage of patients that 
were stratified correctly at four, six, twelve and twenty-four months. At four and six 
months, survival data from patients classified in the worst prognostic group of each 
model were used (e.g. Tomita category ‘Terminal’ or Bauer category ‘Supportive 
care’) and at twelve and twenty-four months survival data from patients classified 
in the best prognostic group of each model were used (e.g. Tomita category ‘Long-
term’ or Bauer category ‘Local control’). 
Table 5. Model performance. Four and six months based on worst prognostic group, twelve and twenty-four 
months based on best prognostic group.
Model % dead within % alive after 
c-statistic  4 months  6 months 12 months 24 months
Tokuhashi
Bauer
Tomita
Van der Linden
Rades
Bollen (all data) 
Bollen (external data)
0.64
0.64
0.64
0.66
0.44
0.70
0.69
62%
64%
65%
64%
69%
75%
67%
74%
76%
78%
77%
81%
86%
83%
61%
58%
68%
80%
37%
80%
82%
39%
35%
47%
60%
22%
60%
65%
The Tokuhashi, Bauer and Tomita models have an identical c-statistic and a 
relatively low predictive ability, both for their worst and best prognostic groups. 
The Van der Linden model has a similar c-statistic, but is much better at identifying 
patients with a longer survival. The Rades model has the lowest c-statistic, but 
shows relatively good predictive power for patients with short survival. However, 
patients with a long survival are poorly identified. The Bollen model has the highest 
c-statistic and is good at identifying patients with short survival and patients with 
long survival. When the results from the external data analysis are observed, the 
c-statistic remains almost identical. However, the number of patients stratified 
correctly at four months drops considerably.
 
DISCUSSION
In this multicenter retrospective study of 1379 patients treated for symptomatic 
SBM it is demonstrated how predictive models perform on a large independent 
dataset. 
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The most important limitation of this study is its retrospective design and the 
possibility of inaccurate interpretation of the source data. Also, the data were 
obtained from centers in two different European countries. Even though the 
quality of oncological care is considered to be excellent, differences in survival 
times between the centers were observed for some primary tumors, possibly 
resulting in lower predictive accuracy of the models. The multivariate analyses 
were adjusted for this center effect.
The Rades model was adjusted due to the fact that information concerning time 
to development of motor deficits could not reliably be obtained. Considering 
that neurologic deficit or ambulatory status were not associated with survival, 
it is unlikely that omitting this variable had a large effect on our results. Also, 
resectability of visceral metastases could not be assessed and all visceral metastases 
were considered unresectable. The effect of this on the accuracy of the Tokuhashi 
and Tomita models is unclear. 
In order to predict survival, the evaluated models utilize a total of seven different 
variables. Each model has different guidelines on how to further categorize 
each variable, leading to different results for identical variables. As has been 
demonstrated, primary tumor, visceral metastases and performance status 
are associated with survival, whereas the number of SBM and the presence of 
extraspinal bone metastases are not.
On multivariate analysis, neurological functioning was also not associated with 
survival. Furthermore, including neurological functioning as a negative predictive 
factor in a model could prove to be disadvantageous. Restoration of ambulatory 
function in patients with acute deficit is the greatest gain possible in the treatment 
of SBM. If the estimated life expectancy would be too short based on a model 
incorporating neurological functioning, this patient would be denied the more 
aggressive, optimal treatment needed to improve his neurological functioning. 
Consequently, the use of a model would undermine, instead of improve the decision-
making process. We therefore carefully suggest that neurological functioning and 
the duration of neurological deficit will be viewed as an indication for treatment, 
instead of a prognostic factor for estimating survival.
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In 1990 Tokuhashi et al. created the first predictive model for SBM19 and the 2005 
revised version9 is still one of the most commonly reported models to date. It 
was based on a retrospective analysis of 246 patients and uses six items to assign 
patients into one of three categories. In this study, three of these items were not 
associated with survival. The primary tumor classification was based on average 
survival periods for each cancer, but due to the low number of patients this was 
not very accurate. Low scores for both the worst and best predictive groups make 
it difficult to justify the use of this model in a clinical setting.
The original Bauer model was based on a retrospective analysis of 88 patients 
with spinal metastases and 153 patients with bone metastases in the extremities. 
Due to the fact that the presence of a pathologic fracture negatively influenced 
survival only in the extremities group, Leithner et al. modified the score for use in 
SBM. Even though it is one of the easiest models to use, the simple primary tumor 
classification and the lack of a performance score resulted in a low accuracy.
The Tomita model was based on a retrospective analysis of 67 patients and essentially 
consists of four items, as the ‘bone metastases’ category includes both spinal and 
extraspinal metastases. The primary tumor classification in slow, moderate and 
fast growing tumors has been shown to be quite accurate. Unfortunately, this 
model also lacks the incorporation of a performance score, resulting in a c-statistic 
identical to the Tokuhashi and Bauer models.
The Van der Linden model was based on 342 patients treated for painful SBM by 
means of radiotherapy within a multicenter randomized phase III trial. The model 
contained all three risk factors that were shown to be associated with survival 
in this article and has a c-statistic of 0.66. It performs better than the previous 
models, especially when identifying patients with a longer expected survival. 
The Rades model was based on a retrospective analysis of 2029 patients, all of 
whom were treated with radiotherapy. With seven items, it is the most elaborate 
score. The aim of this model was to identify patients with poor survival who may 
be candidates for best supportive care and it achieved this goal. In a clinical setting 
however, patients with a longer survival also need to be identified correctly and 
the model fails to do so. It is the only score that takes time to development of SBM 
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into account. This variable was associated with survival on multivariate analysis 
and could potentially be used to increase the accuracy of the predictive models.
Lastly, the recently published Bollen model was based on a retrospective analysis 
of 1043 patients treated with surgery and radiotherapy. Essentially a hybrid of the 
Tomita and Van der Linden models, it has quite good results on both the short and 
long end of the survival spectrum. Even though the primary tumor classification 
is reasonably accurate, it still requires further specification of the malignancies in 
order to increase the discriminative ability.
CONCLUSION
This study provides an insight on how the available SBM models perform on a 
large dataset. The results suggest that the Bollen model performs best when 
identifying patients with a short and patients with a long expected survival. With 
the predicted survival outcome, appropriate choices for treatment can be made by 
patients and their treating physicians.
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ABSTRACT
Objective. To determine the predictive value of the Spinal Instability Neoplastic 
Score (SINS) in a cohort of patients treated with radiotherapy for spinal bone 
metastases.
Summary of background data: Assessment of spinal stability in metastatic disease 
is challenging and is mostly done by relying on clinical experience, in the absence 
of validated guidelines or an established predetermined set of risk factors. The 
SINS provides clinicians with a tool to assess tumor-related spinal instability.
Methods. A total of 110 patients were included in this retrospective study. Time 
to event was calculated as the difference between start of radiotherapy and date of 
occurrence of an adverse event or last follow-up, with death being considered a 
competing event. A competing risk analysis was performed to estimate the effect 
of the SINS on the cumulative incidence of the occurrence of an adverse event. 
Results. Sixteen patients (15%) experienced an adverse event during follow-
up. The cumulative incidence for the occurrence of an adverse event at 6 and 
12 months was 11.8% (95%CI 5.1%-24.0%) and 14.5% (95%CI 6.9%-22.2%), 
respectively. Competing risk analysis showed that the final SINS classification 
was not significantly associated with the cumulative incidence of an adverse event 
within the studied population.
Conclusion. The clinical applicability of the SINS as a tool to assess spinal instability 
seems limited.
57647 Laurens Bollen.indd   98 05-08-19   09:44
SINS
99
VII
INTRODUCTION 
Spinal bone metastases (SBM) develop in up to 70% of cancer patients1. Back 
pain and neurological deficit are the most frequently reported symptoms2-4. 
Current management of SBM focuses on optimizing a patient’s quality of life by 
providing effective pain relief and preserving or restoring neurological function2. 
In addition, spinal instability is a third indication for treatment, as it can lead to 
the aforementioned symptoms. Whereas patients with stable spines can be treated 
using non-invasive procedures such as radiotherapy, patients with unstable spines 
potentially require surgical fixation, either through minimally invasive techniques 
such as percutaneous stabilization or through more invasive procedures involving 
open fixation.
Assessment of spinal stability is challenging and is mostly done by relying 
on clinical experience, in the absence of validated guidelines or an established 
predetermined set of risk factors. The absence of a standardized approach hinders 
communication between physicians of different medical specialties and can result 
in under- as well as overdiagnosis of spinal instability. 
In 2010, the Spinal Oncology Study Group introduced the Spinal Instability 
Neoplastic Score (SINS); the first consensus-based guideline that aids in the 
assessment of a patient’s risk of spinal instability in the setting of neoplastic spinal 
disease5. The SINS determines tumor-related instability based on six criteria and 
classifies the spinal column as stable, potentially unstable or unstable. Surgical 
consultation is recommended for patients with a spinal column classified as either 
potentially unstable or unstable. As such, the SINS facilitates interdisciplinary 
communication, assesses and categorizes spinal instability and optimizes treatment 
decision making.
Previous studies have already shown that the SINS has a substantial to excellent 
inter-observer and intra-observer reliability6-9. Nevertheless, for it to be useful 
in clinical practice, it should also be evaluated whether the score is indeed 
predictive of progressive spinal instability when applied to longitudinal patient 
cohorts. Studies have shown that the total SINS score is not predictive for new or 
progressive vertebral compression fractures (VCF) in patients receiving high dose 
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stereotactic radiotherapy 10-12. Therefore, the role of SINS in assessing this specific 
endpoint is debatable.
The aim of the current study was to determine the predictive value of the total 
and individual components of the SINS system for spinal instability in a cohort 
of patients with spinal bone metastases, treated with radiotherapy. Secondly, the 
interobserver agreement of both the total categorical SINS score and the individual 
components was determined. 
 
PATIENTS AND METHODS
All consecutive patients who were treated with radiotherapy for symptomatic 
SBM between January 2000 and December 2010 in the Leiden University Medical 
Center, the Netherlands, and also had pretreatment computed tomography (CT) 
imaging were eligible for inclusion in this retrospective cohort study. In order 
to ensure accurate correlation between the clinical situation and the obtained 
images, the maximum accepted time between the diagnostic CT scan and start 
of treatment was two months. Patients who had already been stabilized were 
excluded, leaving the patients in whom there is clinical equipoise regarding the 
best treatment strategy and thus reflecting the more important clinical scenario 
in daily practice. Only a single metastatically affected vertebra was evaluated per 
patient. This selection was determined based on inclusion within the radiation 
field. If multiple vertebrae within the same radiation field were affected by 
metastatic disease, the vertebra with the highest score on the SINS components 
location or vertebral body collapse was selected for the analysis. 
Each vertebral segment was scored according to the SINS criteria as described by 
Fisher et al5. The individual SINS components consisted of location (junctional, 
mobile, semi-rigid, and rigid spine), type of pain (mechanical, non-mechanical, 
pain-free), type of lesion (lytic, mixed, sclerotic), spinal alignment (subluxation/
translation, kyphosis/scoliosis, normal), presence of baseline VCF (>50% collapse, 
<50% collapse, no collapse but >50% of the body involved, or none of the above), 
and whether the tumor involved the posterolateral elements (bilateral, unilateral, 
none). The radiological SINS components bone lesion, alignment, vertebral 
body collapse, and posterolateral involvement of spinal elements were assessed 
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independently by four expert observers (SD; orthopedic surgeon, YL; radiation 
oncologist, CR; radiologist, and WP; neurosurgeon). The observers were blinded 
to the patients’ event status. The SINS components pain and location were assessed 
by one observer (LB) based on the patients’ clinical files and admission forms. 
Based on the values for the individual SINS components, the total score was 
calculated and the spine was classified as being stable, potentially unstable or 
unstable5. 
Patient characteristics were assessed using de Karnofsky Performance Status 
(KPS)13 and the Frankel classification14. Expected survival of each individual patient 
was determined using the Bollen model15. Clinical and/or radiological follow-up 
data for instability was collected until 12 months after initial radiotherapy. The 
end points of the study were considered adverse events after radiotherapy and 
consisted of (1) the development of a new pathologic fracture, (2) progression of an 
existing pathologic fracture, and (3) deterioration of alignment requiring surgical 
stabilization of the irradiated spinal segments. The occurrence of an adverse event 
was determined using patients’ medical charts and/or follow-up imaging. 
Statistical analysis
Interobserver agreement between all four observers was calculated using Fleiss’ 
kappa16. The level of agreement for the obtained kappa was determined according 
to Landis et al.17 Survival curves were estimated by using Kaplan-Meier method 
and follow-up was assessed by using the reverse Kaplan-Meier method18. Survival 
times were calculated as the difference between start of treatment and date of 
death or last follow-up. Time to event was calculated as the difference between 
the date of treatment and date of occurrence of an adverse event or last follow-
up, with death being considered a competing event. The cumulative incidence 
for the occurrence of an adverse event at six and twelve months was assessed by 
using a competing risk model19. Sensitivity, specificity, negative predictive value 
(NPV) and positive predictive value (PPV) were calculated for all observers. The 
results of the observer with the highest sensitivity and specificity were used to fit 
univariate and multivariate Fine and Gray models20, in order to estimate the effect 
of the risk factors on the cumulative incidence of the event. In order to perform 
the sensitivity analysis and the Fine and Gray’s regression analysis, the final SINS 
categories were reduced from three to two, aggregating the categories unstable and 
potentially unstable versus the category stable6,9. A P-value <0.05 was considered 
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statistically significant. Statistical analyses were performed using SPSS version 
20.0, Armonk, NY and R version 2.18.
 
RESULTS
A total of 997 patients were treated with radiotherapy for spinal bone metastases 
during the study period. Of these, 236 patients underwent a CT scan within two 
months before starting treatment. Patients without clinical and/or radiological 
follow-up were excluded and a total of 110 patients remained eligible for analysis.
Table 1 summarizes the characteristics of the study population. Fifty-nine patients 
(54%) were male and the mean age at the start of treatment was 60.4 years (SD 
± 13.8 years). The Karnofsky Performance Status was normal (100%-80%) in 59 
patients (54%) and 107 patients (97%) had no, or only minor motor and sensory 
deficit. The prognostic category for survival according to the Bollen model was 
good in six patients (5%), moderate in 28 patients (26%), poor in 57 patients (52%) 
and very poor in 14 patients (13%). Thirty-six patients (33%) were treated with a 
single fraction of 8 Gy, 26 patients (24%) with two fractions of 8 Gy and 48 patients 
(43%) were treated with more than two fractions, totaling a dose of 24 Gy or more.
Figure 1. Cumulative incidence of adverse events and death for the entire cohort
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Table 1. Patient characteristics.
Characteristic N (%)
Gender
   Male
   Female
Age (years, mean ± SD)
Primary tumor
   Lung   
   Breast
   Kidney 
   Colon
   Esophagus
   Prostate 
   Other
Karnofsky performance status
   Normal (100-80%)
   Impaired (70-10%)
   Missing
Frankel classification
   No deficit (E)
   Minor motor or sensory deficit (D)
   Major motor or sensory deficit (A,B,C)
Expected survival
   A - Good
   B - Moderate
   C - Poor
   D – Very poor
   Missing 
Total radiotherapy dose
   8 Gy
   16 Gy
   ≥24 Gy
59 (54)
51 (46)
60.4 ± 13.8
25 (23)
18 (16)
17 (16)
14 (13)
9 (8)
8 (7)
19 (17)
59 (54)
46 (42)
5 (4)
67 (61)
40 (36)
3 (3)
6 (5)
28 (26)
57 (52)
14 (13)
5 (4)
36 (33)
26 (24)
48 (43)
 
The overall median survival was 6.6 months (95%CI 5.5-7.7) with a median 
follow-up of 5.2 years. Seventy-nine patients (72%) died within 12 months after 
starting treatment. A total of 16 patients (15%) experienced an adverse event 
during follow-up. Among them, eight patients (50%) experienced a deterioration 
of spinal alignment for which they were surgically stabilized and eight patients 
(50%) experienced a pathologic fracture, or progression of their existing fracture. 
In figure 1 the cumulative incidence of the two competing events is illustrated. The 
cumulative incidences for the occurrence of an adverse event at 6 and 12 months 
were 11.8% (95%CI 5.1%-24.0%) and 14.5% (95%CI 6.9%-22.2%), respectively.
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Table 2 shows the SINS scores for each individual observer. The level of agreement 
between all four observers for the final SINS score was moderate (κ=0.536, p<0.001). 
The level of agreement was fair for the components bone lesion (κ=0.299, p<0.001) 
and spinal alignment (κ=0.358, p<0.001), whereas the components vertebral body 
collapse (κ=0.453, p<0.001) and posterolateral element involvement (κ=0.436, 
p<0.001) had a moderate level of agreement.
Table 2. Individual Spinal Instability Neoplastic Score and Fleiss’ kappa. *) Variables location and pain were 
determined separately and therefore identical among all four observers.
SINS Kappa Observer 1
N (%)
Observer 2
N (%)
Observer 3
N (%)
Observer 4
N (%)
Bone lesion
   Lytic
   Mixed
   Blastic
Spinal alignment
   Subluxation/translation
   Kyphosis/scoliosis
   Normal alignment
Vertebral body collapse
   >50% Collapse
   <50% Collapse
   None, >50% involvement
   None of the above
Posterolateral elements
   Bilateral
   Unilateral
   None
Location*
   Junctional
   Mobile spine
   Semi-rigid
   Rigid 
Pain*
   Yes; mechanical pain
   Yes; non-mechanical pain
   No   
Total SINS score
   Stable (0-6 points)
   Uncertain (7-12 points)
   Unstable (13-18 points)
0.299
0.358
0.453
0.436
-
-
0.536
88 (80)
17 (16)
5 (4)
1 (1)
12 (11)
97 (88)
14 (13)
27 (24)
22 (20)
47 (43)
12 (11)
28 (25)
70 (64)
50 (55)
25 (23)
35 (32)
0 (0)
24 (22)
80 (73)
6 (5)
50 (46)
55 (50)
5 (4)
70 (64)
29 (26)
11 (10)
3 (3)
8 (7)
99 (90)
15 (14)
41 (37)
14 (13)
40 (36)
27 (25)
43 (40)
40 (36)
50 (55)
25 (23)
35 (32)
0 (0)
24 (22)
80 (73)
6 (5)
41 (37)
63 (57)
6 (6)
80 (73)
19 (17)
11 (10)
4 (4)
7 (6)
99 (90)
16 (15)
28 (25)
39 (36)
27 (24)
43 (39)
36 (33)
31 (28)
50 (55)
25 (23)
35 (32)
0 (0)
24 (22)
80 (73)
6 (5)
31 (28)
70 (64)
9 (8)
51 (46)
45 (41)
14 (13)
1 (1)
20 (18)
89 (91)
14 (13)
49 (44)
23 (21)
24 (22)
23 (21)
24 (22)
63 (57)
50 (55)
25 (23)
35 (32)
0 (0)
24 (22)
80 (73)
6 (5)
37 (34)
70 (63)
3 (3)
 
Table 3 shows the sensitivity, specificity, positive predictive value and negative 
predictive value of the SINS for all four observers. Sensitivity ranged from 35%-
69%, specificity from 18%-48%, positive predictive value from 6%-18% and 
negative predictive value from 63%-90%.
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Table 3. Evaluation of SINS accuracy. PPV: positive predictive value. NPV: negative predictive value.
Sensitivity Specificity PPV NPV
Observer 1
Observer 2
Observer 3
Observer 4
69%
35%
35%
41%
48%
27%
18%
25%
18%
7%
6%
8%
90%
71%
63%
71%
 
Univariate Fine and Gray analysis showed that the final SINS classification, 
total radiotherapy dose, as well as the six individual SINS components were 
not significantly associated with the cumulative incidence of an event (table 
4). The multivariate analysis included all six SINS components as well as total 
radiotherapy dose. Only the component location was significantly associated with 
the cumulative incidence of an adverse event with a hazard ratio of 0.54 (95%CI 
0.30-0.96, p=0.04) (table 4).
Table 4. Results of the univariate and multivariate Fine and Gray models. HR: hazard ratio. CI: confidence 
interval.
Univariate Fine and Gray HR 95% CI p-value
Location
Pain
Bone lesion
Spinal alignment
Vertebral body collapse
Posterolateral elements
Total SINS score
Total dose
0.71
0.53
1.90
1.01
0.96
1.28
2.01
1.02
0.42-1.31
0.22-1.13
0.33-10.89
0.53-1.95
0.61-1.51
0.86-1.90
0.73-5.62
0.96-1.07
0.22
0.09
0.47
0.97
0.85
0.22
0.19
0.53
Multivariate Fine and Gray HR 95% CI p-value
Location
Pain
Bone lesion
Spinal alignment
Vertebral body collapse
Posterolateral elements
Total dose
0.54
0.40
1.32
1.06
0.64
1.15
1.01
0.30-0.96
0.13-1.17
0.25-7.02
0.46-2.40
0.32-1.29
0.64-2.08
0.95-1.08
0.04
0.10
0.75
0.90
0.21
0.65
0.79
 
DISCUSSION
In this single center retrospective study it is demonstrated how the Spinal 
Instability Neoplastic Score performs on an independent dataset consisting of 110 
patients undergoing external beam radiation therapy for symptomatic spinal bone 
metastases. Competing risk analysis showed that the SINS classification was not 
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significantly associated with the cumulative incidence of an adverse event within 
the studied population.
The levels of agreement found in this study were obtained by calculating Fleiss’ 
kappa based on the results of four highly experienced observers and ranged from 
fair to moderate. The results were comparable to those obtained in previous 
studies6-8. Especially the SINS component bone quality, describing the lesion as 
being lytic, blastic, or mixed, continues to be a challenge for observers to agree 
upon, ranging from only 0.21 to 0.306-8. 
Apparently, although seemingly objective, measures such as displacement and 
kyphosis, are still difficult to interpret, even for highly experienced clinicians. 
Previous research comparing the interobserver agreement between groups of 
similar specialist (e.g. orthopedic surgeons vs. no orthopedic surgeons and 
surgeons vs. radiation oncologists), has shown that the clinicians’ background 
seems to affect their agreement on the total SINS score as well as different 
components of the SINS8,9. Accordingly, a mixed group of clinicians agrees less 
than, for example, a group of experienced orthopedic surgeons. It has also been 
shown that experience affects the degree of agreement. Highly experienced spine 
surgeons agree more than less experienced spine surgeons8.
The highest levels of sensitivity and specificity found in this study (69% and 48%) 
differed considerably when compared to the levels found in the study performed 
by Fourney et al. (96% and 80%)6. This might be attributed to the fact that Fourney 
et al. used consensus opinion to a priori define a metastatic spine as either stable or 
unstable, whereas in this study actual clinical endpoints were used to define stable 
and unstable spines. Nonetheless, a sensitivity of 69% suggests a good capacity 
to identify patients with a low risk of complication due to spinal instability. In 
clinical practice, this could translate to fewer surgical consultations for patients 
who are classified as stable according to the SINS. On the other hand, the rather 
low specificity found in this study indicates that no treatment decisions should 
be made based on the classifications potentially unstable and unstable. In daily 
practice, surgical consultation is still warranted for these categories.
In line with previously reported studies10,11, no predictive value of the total SINS 
score was observed for the occurrence of an adverse event. Total radiotherapy 
57647 Laurens Bollen.indd   106 05-08-19   09:44
SINS
107
VII
dose and the individual SINS components, pain, bone lesion, alignment, collapse 
and posterolateral involvement did not show a significant association with the 
occurrence of an adverse event in the multivariate analysis. Even though the 
component location reached a significant level of association, a hazard ratio of less 
than one is indicative of a protective effect for developing spinal instability, rather 
than a harmful effect, as implied by the SINS. As a result, this variable might not 
provide any clinically relevant information when assessing spinal instability.
Similar to our study, Lam et al.21 retrospectively examined the relationship of 
the SINS and dose fractionation with the development of a spinal adverse event 
(SAE) in 299 patients with SBM who received radiotherapy. They found that a 
SINS score ≥ 11 and a single fraction of 8 Gy were independent predictors for the 
development of an SAE. However, the definition of an event was much broader 
than in the current study. For instance, hospitalization due to pain at the irradiated 
site was considered an SAE, constituting 37% of all events. It is unlikely that the 
SINS can evaluate hospitalization due to pain and including it as an adverse event 
could potentially obscure the results.
In contrast to our study, Cunha et al.11 found an association between the 
components spinal alignment and lesion type on the occurrence of a VCF and 
Sahgal et al.10 found an association between spinal alignment, lesion type and 
vertebral body collapse on the occurrence of a VCF. The major difference is that 
these two studies reported on patients who underwent high-dose stereotactic 
radiotherapy, potentially resulting in more VCFs whereas the population in this 
study underwent relatively low-dose radiotherapy.
A limitation of the current study is the retrospective design. The SINS component 
pain was determined based on patient charts and intake forms, possibly resulting 
in inaccurate interpretation of the data. The availability of pretreatment CT scans 
was limited (236/1042, 23%), reducing the overall population count. 
Although patients who presented with evident clinical spinal instability and 
were operated on are not represented in this study, our analysis reflects the more 
important daily clinical scenario. The main treatment for patients with painful 
bone metastases is radiotherapy. Since these patients have limited survival, spinal 
surgery must only be applied in case of a reasonable and stable clinical condition. 
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One aims to prevent that patients treated with radiotherapy will undergo an 
adverse event in their follow up. Thus, especially in this heterogenous patient 
group in terms of amongst others primary tumor, physical condition and referring 
physician, in which a limited risk of spinal instability is expected, it is of utmost 
importance to identify those patients who, after radiotherapy, underwent an event 
and perhaps would have gained more in terms of sustaining quality of life if a 
surgical stabilizing procedure had been performed instead of radiotherapy. By 
including only patients treated with radiotherapy, we focused on this clinically 
important group in which there is some clinical equipoise. Therefore, leaving out 
patients who were primary stabilized did not result in major selection bias.
Strengths of the study are the number of observers and the fact that highly 
experienced clinicians of four different medical disciplines involved with treatment 
of SBM were represented. Although there was limited agreement between the four 
observers, our panel’s constitution reflects clinical practice as in everyday reality 
spinal instability is often assessed separately by individual clinicians. Although a 
multidisciplinary meeting would seem most fitting to discuss instability and agree 
on appropriate treatment, due to the often swift course of disease and symptoms, 
such weekly meetings take place too late. Also, the endpoints used are clinically 
relevant. Whereas other validation studies compared the SINS outcome to 
predetermined consensus-based cases of stable and unstable spines, in the current 
study, actual clinical data were used as outcome measure.
Even though the authors agree that the components constituting the SINS 
classification are potentially important factors to consider when assessing spinal 
instability, in its current form, clinical applicability seems limited. As a tool for 
streamlining communication between physicians of different medical specialties 
and facilitating the decision making concerning surgical consultation, the SINS 
could be useful. 
A prospective CT-based study with clear clinical endpoints might help determine 
the relative importance of each component in predicting complications resulting 
from spinal instability and could result in an adjustment of the points allocated 
to each component, as well as the grouping of each variable. As this study and 
the study performed by Teixeira et al.8 have shown, panels consisting of reviewers 
from different medical specialties can result in lower levels of agreement, whereas 
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a panel consisting of observers from one specialty can result in very high levels of 
agreement.9 Therefore, the optimal reviewing panel for such a study remains to 
be determined, but it seems observers from a surgical specialty generally have the 
highest level of agreement.   
In conclusion, this study provides an insight into the ability of the SINS to assess 
spinal instability in patients undergoing external beam radiation therapy for spinal 
bone metastases. Based on these results, the clinical applicability of the SINS as a 
tool to assess spinal instability seems limited.
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Spinal bone metastases (SBM) are a multifactorial and multidisciplinary clinical 
entity. Patient-specific symptoms, life expectancy, spinal stability and patient 
preference all need to be evaluated, in order to provide a balanced treatment.
Chapter II described a systematic review of risk factors associated with estimating 
survival in patients with SBM. In the 22 included studies, the prognostic factors 
most frequently associated with survival were the primary tumor and the 
performance status. The prognostic factors most frequently not associated with 
survival were age, gender, number and location of the SBM and the presence of a 
pathologic fracture. Models aiming to provide a prognosis for patients with SBM 
should be based on an accurate primary tumor classification, combined with a 
performance score. The benefit of adding other prognostic factors was considered 
uncertain. 
Chapter III evaluated risk factors for survival in a surgical cohort of 106 patients 
operated for SBM. Even though the study was performed prior to the systematic 
review of chapter II, the results are almost identical.
The large retrospective cohort study described in Chapter IV was the basis of this 
thesis and described the creation of our own predictive model for life expectancy 
in SBM. By using the presented flowchart and assessing the primary tumor type, 
functional status and the presence of visceral metastases, a patient is stratified to 
a risk category. This risk category corresponds with a median overall survival and 
provides a decent measure of certainty when assessing life expectancy.
Chapter V aimed to further fine-tune the most important variable in estimating 
survival, namely the primary tumor type. Along with lung and prostate cancer, 
breast cancer is the most common cause of SBM. Predictive models do not take 
breast cancer phenotypes based on estrogen (ER), progesterone (PR) and human 
epidermal growth factor 2 (HER2) receptors into account. The aim of this study 
was to ascertain whether receptors are associated with survival, when the disease 
has progressed up to the point of SBM. Patients with SBM from breast cancer 
with a triple negative phenotype have a shorter survival time than patients with a 
receptor positive phenotype, showing that models estimating survival should be 
adjusted accordingly.
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Chapter VI assessed the performance of six predictive models, including our own, 
on an independent dataset. The Tokuhashi, Bauer, Tomita and Van der Linden 
models performed similar with a c-statistic of 0.64-0.66 and a 4-month accuracy 
of 62-65%. The Rades model (c-statistic 0.44) and Bollen model (c-statistic 0.70) 
had a 4-month accuracy of 69% and 75%, respectively. We therefore concluded 
that the model created in Chapter IV outperformed the models created prior to 
this thesis.
Chapter VII aimed to determine the predictive value of the Spinal Instability 
Neoplastic Score (SINS) in a cohort of patients treated with radiotherapy for SBM. 
Assessment of spinal stability in metastatic disease is challenging and is mostly 
done by relying on clinical experience, in the absence of validated guidelines or 
an established predetermined set of risk factors. The SINS provides clinicians with 
a tool to assess tumor-related spinal instability. However, as was shown in this 
chapter, clinical applicability of the SINS as a tool to assess spinal instability seems 
limited.
Finally, Chapter IX draws the conclusions and clinical implications of this thesis 
and future perspectives for the treatment of SBM are also discussed.
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Metastases to the spinal column in patients with end-stage malignant disease are a 
frequently observed complication of. Depending on their extent and localization, 
they cause a variety of clinical symptoms ranging from pain to neurological deficits 
and even paraplegia. Due to improvements in systemic treatment options for the 
primary tumor, overall survival times in patients suffering from metastatic disease 
are on the rise.1,2 Most likely, this will result in a prolonged palliative phase in which 
the incidence of patients presenting with symptomatic spinal bone metastases 
(SBM) will increase. Treatment with radiotherapy and/or surgery can be beneficial 
to patients presenting with pain, neurological deficit or both.3-5 However, the most 
optimal treatment algorithm for individual patients has not yet been established. 
In practice, the treating physician will match extent and type of treatment not 
only to a patient’s clinical presentation, but also to the expected survival time, thus 
balancing the increase in morbidity and mortality associated with more extensive 
treatment to the expected gain in quality of life.
Survival
Prediction of survival has become an integral part of selecting the appropriate 
treatment for patients suffering from SBM. Depending on the symptoms, 
patients with a short expected survival are most likely to benefit from short 
radiotherapy regimens, best supportive care or minimally invasive surgery. 
Patients with a relatively long expected survival could potentially benefit from 
high dose radiotherapy or – in the case of radioresistant tumors and (impending) 
biomechanical instability – more extensive surgical interventions. Several studies 
have shown that the estimation of survival by clinicians in terminally ill patients 
is inaccurate6 and have suggested the use of prognostic models in order to prevent 
exposure of patients to unnecessarily extensive treatments. Models that can be used 
in the decision making process have been developed by Tokuhashi, Bauer, Tomita, 
Van der Linden, Rades and several others.7-11 These models include prognostic 
factors such as primary tumor type, amount and location of spinal metastases, 
presence of visceral, brain and extraspinal bone metastases, functional status and 
neurological status.
However, clinical applicability seems limited due to over- or undertreatment and 
especially when predicting short survival the existing models fall short. Therefore, 
after an assessment of risk factors in a surgical cohort of patients described 
in Chapter III, we decided to create a new model. In the study described in 
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Chapter IV, 1043 patients who were treated for symptomatic SBM were evaluated. 
Overall median survival of the entire cohort was short, with just 4.8 months (95%-
CI 4.3-5.4). Patients were stratified according to the clinical profile of their primary 
tumor: favorable (e.g. breast), moderate (e.g. prostate) or unfavorable (e.g. lung), 
after which all risk factors that might be associated with survival were evaluated 
with a multivariate analysis. It was shown that survival in patients with SBM from a 
favorable clinical profile was influenced by the presence of visceral metastases and 
brain metastases, as well as the performance status. In patients with a moderate or 
unfavorable clinical profile, only performance status was associated with survival. 
Based on these results a flowchart was created, stratifying patients into four 
categories (A-D) with significantly different survival. Patients in category A had 
a median overall survival of 31.2 months (95%CI 25.2-37.3), compared to 15.4 
months (95%CI 11.9-18.2) for patients in category B, 4.8 months (95%CI 4.1-5.4) 
for patients in category C and 1.6 months (95%CI 1.4-1.9) for patients in category 
D. Predictive accuracy of the model was assessed by using Harrell’s C-statistic,12 
which was equal to 0.71, indicating reasonable discriminative accuracy. A C-index 
equal to one means that the model has perfect discrimination and a C-index equal 
to 0.5 means that the model predicts just as well as flipping a coin.
It has been shown that the primary tumor causing the SBM is the strongest 
predictor of survival. Patients with symptomatic SBM from breast cancer tend to 
live longer than patients with SBM from, for instance, lung cancer. This is reflected 
in all predictive models, where breast cancer is considered a favorable prognostic 
factor, compared to other primary cancers.
Based on estrogen receptor status (ER), progesterone receptor status (PR) and 
human epidermal growth factor receptor 2 status (HER2), several molecular 
phenotypes of breast cancer can be distinguished.13,14 It is known that these 
phenotypes are associated with survival when measured from the time of diagnosis 
of the primary tumor, however, it is unclear whether this effect remains when the 
disease has progressed up to the point of symptomatic SBM. If so, the manner in 
which our predictive model stratifies patients needs to be adjusted, distinguishing 
between different breast cancer phenotypes. In Chapter V we examined this effect 
by combining all breast cancer patients from our database, with all breast cancer 
patients from two external databases from Graz, Austria and Aarhus, Denmark. 
Based on the ER, PR and HER2 expression, tumors were further subdivided into 
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four categories; luminal A, luminal B, HER2 and triple negative. The luminal A 
subtype is ER positive and/or PR positive without HER2 overexpression. The 
luminal B subtype is ER positive and/or PR positive with HER2 overexpression. 
The HER2 subtype is ER and PR negative, with HER2 overexpression. Finally, the 
triple negative subtype is negative for all three receptors. Median survival times 
in the luminal A, luminal B and HER2 categories were not significantly different, 
whereas the median survival time in the triple negative category was much shorter. 
Median survival in the triple negative category was 5.5 months (95%CI 2.0-9.0), 
whereas survival in the other three combined receptor positive phenotypes was 
23.4 months (95%CI 19.0-27.8) (log-rank test p<0.001). Based on this information 
we changed our primary tumor classification, by moving triple negative breast 
cancer patients into the ‘moderate’ clinical profile. All receptor positive phenotypes 
remained in the ‘favorable’ clinical profile. The adjustment resulted in an increase 
of 5% of the c-statistic calculated for this specific cohort.
Analogous to the study described above, Willeumier et al. studied the effect of 
epidermal growth factor receptor (EGFR) mutations in patients presenting with 
bone metastases from non-small cell lung cancer.15 It was shown that survival in 
patients with EGFR-positive tumors was much longer, due to the advent of new 
systemic treatment options. 
As stated above, the aim was to develop a more accurate model than the ones 
available at the time. In order to ascertain whether we had achieved this, in 
Chapter VI we compared our own model to the ones created by Tokuhashi, Bauer, 
Tomita, Van der Linden and Rades.7-11 A database containing 1379 patients was 
created by combining our own data with data from Graz, Austria. All models were 
fitted with the available patient information and survival times and c-statistics 
were calculated for each model. Results showed that all models performed within 
a similar range (c-statistic 0.64-0.69), with our own model slightly outperforming 
the older models. A recently published study by Nater et al. evaluated a total of 
eight predictive models based on prospectively collected data in 142 surgically 
treated patients.16 C- statistics found in this study ranged from 0.61 to 0.68, similar 
to our own study.
In 2015, the Dutch national guideline on spinal metastases was updated and one of 
the topics addressed was the estimation of survival. In order to investigate which 
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risk factors are associated with survival, a systematic review was performed, which 
is described in Chapter II. After screening 2989 abstracts, 142 full-text papers were 
evaluated for eligibility. In total 22 studies were included, describing a total of 43 
different prognostic factors, of which 17 were relevant to pre-treatment survival 
estimation. The prognostic factors most frequently associated with survival were 
the primary tumor and the performance status. The prognostic factors most 
frequently not associated with survival were age, gender, number and location of 
the SBM and the presence of a pathologic fracture. The evidence was inconclusive 
for the presence of visceral metastases and the presence of neurologic deficit. 
Therefore, prognosis of survival for patients with SBM should be based on an 
accurate primary tumor classification, combined with a performance score. The 
benefit of adding other prognostic factors was considered doubtful.
Stability
Next to life expectancy, spinal stability is one of the key factors to examine when 
deciding on treatment. Whereas patients with stable spines can be treated using 
non-invasive procedures such as radiotherapy, patients with unstable spines 
potentially require surgical fixation, either through minimally invasive techniques 
such as percutaneous stabilization or through more invasive procedures involving 
open fixation.
Assessment of spinal stability is challenging and in the absence of validated 
guidelines or an established predetermined set of risk factors, is mostly done 
by relying on clinical experience and radiological imaging. The absence of a 
standardized approach hinders communication between physicians of different 
medical specialties and can result in under- as well as overdiagnosis of spinal 
instability. 
In 2010, the Spinal Oncology Study Group introduced the Spinal Instability 
Neoplastic Score (SINS); the first consensus-based guideline that aids in the 
assessment of a patient’s risk of spinal instability in the setting of neoplastic spinal 
disease.17 The SINS determines tumor-related instability based on six criteria and 
classifies the spinal column as stable, potentially unstable or unstable. Surgical 
consultation is recommended for patients with a spinal column classified as either 
potentially unstable or unstable. As such, the SINS facilitates interdisciplinary 
communication, assesses and categorizes spinal instability and assists in treatment 
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decision making. In Chapter VII we aimed to evaluate the SINS in a clinical setting, 
based on an analysis of 110 patients who were treated for SBM. Even though 
previous studies by the original authors have shown that the SINS has a substantial 
to excellent inter-observer and intra-observer reliability, the kappa-values found 
in this paper and several others18,19 differed considerably when compared to the 
levels found in the studies performed by Fourney et al. and Fisher et al.20,21 Also, 
the multivariate competing risk analysis showed that only the component location 
was significantly associated with the cumulative incidence of an adverse event, 
however a hazard ratio of 0.54 (95%CI 0.30-0.96, p=0.04) for this item indicates 
a protective effect for developing an adverse event. Even though the components 
constituting the SINS classification are important factors to consider when 
assessing spinal instability, in its current form, clinical applicability in predicting 
for the occurrence of a vertebral compression fracture seems limited.22,23 As a 
tool for streamlining communication between physicians of different medical 
specialties and facilitating the decision making concerning surgical consultation, 
the SINS could be useful.24
Future Perspectives
In their current form and with the current set of known risk factors, it would seem 
that the predictive models have reached a plateau with a c-statistic in the range 
of 0.6-0.7.16,23 By further fine-tuning the most important variable – the primary 
tumor – improvements can still be made,15,25 but it is doubtful that a value of 0.8 or 
higher, indicating very good predictive capability, will be reached. This by no means 
implies that we should abandon our attempts at improvements, as the routine use 
of these models does provide clinicians with useful feedback concerning survival 
estimations, which are generally speaking too positive.6 
As treatments for different cancer types tend to differ considerably between 
countries, let alone continents, it is unlikely that a model created based on data 
from the Netherlands could be applied seamlessly in  Japan or the United States. 
We experienced this during our attempts to integrate data from Austria into our 
own database. Even in the larger cancer-specific groups such as prostate cancer, 
survival times differed considerably between the two countries. This underlines 
the need for a more adaptive approach when evaluating the models, where the 
framework (i.e. the risk factors) would remain the same, but the way in which 
points are assigned or patients are stratified is adjusted according to regional data. 
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For instance, in our paper described in Chapter VI, we noticed early on that the 
Rades model would do poorly, based on its weighing of the primary tumor types. 
The points assigned differed greatly from the survival times in our cohort, leading 
to a very low c-statistic. Had we optimized this category, we would have been 
able to better assess whether the combination of risk factors is of value. Now we 
only learned that a rigid translation of the model is not applicable to our dataset. 
Continuous updating and fine-tuning of the predictive models is needed to ensure 
their clinical applicability. Considering the above, it is not unlikely that our model 
will require  some adaptations, since it is based on data collected from patients 
who were treated between 2000 and 2010. This update could then be implemented 
in the recently released OPTIModel app for Android and iOS (available for free 
in the Google Play Store and the App Store). The OPTIModel is a tool to estimate 
survival in patients with bone metastases to the spinal column and long bones, 
based on the work described in this thesis and papers by Willeumier et al.26
Where stability is concerned, it is unlikely that the SINS will fill the role of a 
predictive tool in its current form. Even as a referral tool for non-surgical clinicians, 
as which it is originally meant, it lacks discriminative capability, as the majority of 
patients end up in the intermediate category. Also, the manner in which the points 
are assigned across the different items seems somewhat arbitrary. For instance, 
patients who experience subluxation or translation of the spinal column are 
awarded four points. One could argue that this is de facto spinal instability and 
a patient should be referred for surgical consultation immediately, irrespective of 
the other items. Considering the vast clinical experience of the authors involved 
in creating the SINS, there is no doubt that the individual items are important in 
assessing the metastatic spinal column. Perhaps a re-imagining and simplification 
of the SINS into major criteria (misalignment, deformity, collapse) and minor 
criteria (location, aspect of the lesion, pain, and posterior involvement) can 
increase its clinical usefulness. 
While the aforementioned adjustments might result in predictive models attaining 
a c-statistic upwards of 0.7 and an increase in the discriminative power of the 
SINS, it is by no means is a great leap forward. All our efforts at optimizing care 
for a patient population as diverse as the one of spinal metastases could improve 
considerably with the advent of machine learning in medicine. In recent years, 
several abstracts have been presented at the annual meeting of the American 
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Society of Clinical Oncology, demonstrating the use of IBM’s Watson for Oncology 
(WFO), a self-learning computing system that is able to provide evidence-based 
treatment recommendations, by processing data from medical literature, treatment 
guidelines, imaging, laboratory results and pathology reports, among many other 
sources. Studies showed a high concordance between recommendations made by 
tumor boards and WFO.27,28 Also, recent work done by Groenen et al. made use 
of finite element modelling to assess spinal stability.29 This is a form of structural 
stress analysis developed in engineering mechanics and can be applied to CT-based 
assessments of the metastatic spine. By further developing this technique, perhaps 
in combination with machine learning, a more robust system for predicting spinal 
instability can be created.30,31
Over the past years, advances in radiotherapy planning techniques as well as 
advances in minimally invasive surgical techniques have opened up entire new 
avenues of treatment. However, in order to adequately deploy these new treatment 
strategies, correct assessment of spinal stability, as well as survival is essential 
in order to avoid overtreatment. In the case of Stereotactic Body Radiotherapy 
(SBRT), the benefit of a faster and longer lasting response must be offset to the 
higher risk of inducing vertebral compression fractures (VCFs). While this 
complication might be an acceptable risk in a curative or oligometastatic setting, 
in a palliative setting, it is not. Ideally, these treatment decisions are made in a 
multidisciplinary setting, including all medical specialties involved in diagnosing 
and treating spinal metastases. 
This thesis provides an insight into the challenges of selecting the appropriate 
treatment for patients presenting with spinal metastases, by considering the 
estimated survival and clinical assessment of spinal instability. Hopefully this 
work can be used to further improve patient and treatment selection and further 
reduce overtreatment of patients in a palliative setting.
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NEDERLANDSE SAMENVATTING
Wervelmetastasen zijn een complex klinisch probleem dat een multidisciplinaire 
aanpak behoeft. Patiëntspecifieke symptomen, levensverwachting, stabiliteit van 
de wervelkolom en voorkeuren van de patiënt dienen allemaal geëvalueerd te 
worden om tot een gedegen behandelbesluit te komen.
In Hoofdstuk II wordt een systematische review beschreven van de risicofactoren 
die worden geassocieerd met het schatten van de overleving van patiënten met 
wervelmetastasen. In de 22 geïncludeerde studies werden de risicofactoren 
primaire tumor en conditie het meest frequent beschreven. De risicofactoren leeftijd, 
geslacht, aantal wervelmetastasen, locatie van de wervelmetastasen en aanwezigheid 
van een pathologische fractuur werden het minst frequent beschreven. Derhalve 
werd geconcludeerd dat prognostische modellen voor het inschatten van de 
overleving van patiënten met wervelmetastasen gebaseerd dienen te zijn op een 
accurate classificatie van de primaire tumor in combinatie met een maat voor de 
conditie van de patiënt. Het nut van het toevoegen van andere risicofactoren aan 
het model is twijfelachtig.
In Hoofdstuk III worden de risicofactoren voor overleving beschreven in een 
cohort van 106 chirurgisch behandelde patiënten. Deze studie werd uitgevoerd 
voorafgaand aan de systematische review uit hoofdstuk II, desondanks waren de 
resultaten nagenoeg identiek.
De retrospectieve cohort studie in Hoofdstuk IV was de basis voor dit proefschrift 
en beschrijft de totstandkoming van ons eigen model om de levensverwachting 
voor patiënten met wervelmetastasen in te schatten. Door de primaire tumor, 
klinische status en de aanwezigheid van viscerale metastasen te evalueren en de 
gepresenteerde flowchart te gebruiken, kunnen patiënten gestratificeerd worden 
in een risicocategorie. Deze risicocategorie correspondeert met een mediane 
overleving en geeft een goede maat voor de verwachtte overleving van de patiënt. 
In Hoofdstuk V is getracht de belangrijkste prognostische variabele – de primaire 
tumor – verder uit te werken. Naast longkanker en prostaatkanker, is borstkanker 
de meest voorkomende oorzaak van wervelmetastasen. Tot op heden maken de 
verschillende voorspellende modellen geen onderscheid tussen de verschillende 
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fenotypen van borstkanker, gebaseerd op de aan- of afwezigheid van oestrogeen 
(ER), progesteron (PR), of Human Epidermal Growth Factor 2 (HER2) receptoren. 
Het doel van deze studie was om vast te stellen of de verschillende fenotypen invloed 
hebben op de overleving, wanneer de ziekte is gevorderd tot de aanwezigheid van 
wervelmetastasen. Het bleek dat patiënten met wervelmetastasen uitgaande van 
borstkanker met het triple negatieve fenotype een kortere overleving hebben. Dit 
houdt in dat de voorspellende modellen een onderscheid dienen te maken tussen 
dit fenotype en de andere vormen van borstkanker met een aanzienlijk betere 
overleving.
In Hoofdstuk VI werden de voorspellende prestaties van zes modellen onder 
de loep gelegd met behulp van een onafhankelijke dataset. De modellen van 
Tokuhashi, Bauer, Tomita en Van der Linden presteerden gelijkwaardig met een 
c-score van 0.64-0.66 en een nauwkeurigheid van 62-65% na vier maanden. De 
modellen van Rades (c-score 0.44) en ons eigen model (c-score 0.70) hadden 
een nauwkeurigheid na vier maanden van respectievelijk 69% en 75%. Derhalve 
concludeerden wij dat het model uit hoofdstuk IV beter presteerde dan de overige 
voorspellende modellen.
In Hoofdstuk VII werd de voorspellende waarde van de Spinal Instability 
Neoplastic Score (SINS) onderzocht in een cohort patiënten met wervelmetastasen 
behandeld met radiotherapie. Het evalueren van de stabiliteit van de wervelkolom 
is bijzonder uitdagend en gebeurt voornamelijk op basis van klinische expertise 
in de afwezigheid van gevalideerde richtlijnen. De SINS voorziet clinici van een 
hulpmiddel om tumor-gerelateerde instabiliteit in te schatten. Echter, de resultaten 
van deze studie lieten geen klinisch nut zien van het gebruik van de SINS bij het 
inschatten van stabiliteit.
Tot slot worden in Hoofdstuk IX de conclusies en klinische impact van dit 
proefschrift besproken, alsmede de toekomstperspectieven aangaande de 
behandeling van wervelmetastasen.
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